



Radiotherapy of localized soft tissue sarcoma

Version 1.3

APPROVAL

Content approval

8th of January 2025 (DSG)

Administrative approval

20th of January 2025 (Center for Clinical Practice Guidelines | Cancer)

REVISION

Planned: 8th of January 2027

KEYWORDS

Sarcoma, Soft tissue, radiotherapy, adults, humans

Revisions to previous version (changelog)

Revisions to version 1.2

Guideline chapter	Description of revisions or additions
Recommendations	References that do not alter the recommendations have been added for recommendations 6, 7, and 18. The text of recommendations 3 and 16, as well as the underlying references, has been revised. In the text for recommendation 3, a Table 1b has been added. Two new recommendations, 21 and 28, have been formulated.

Content

Content.....	1
1. Anbefalinger – Dansk (Quick guide).....	3
Indikationer.....	3
Timing og interval.....	3
Dosis og fraktionering.....	4
Target definition	4
Teknik	5
Site-specifik strålebehandling.....	5
Histologisk specifik strålebehandling.....	6
Proton behandling	6
Recommendations English (Quick guide)	7
Indications.....	7
Timing and interval.....	7
Dose and fractionation	8
Target definition	8
Technique	9
Site specific radiotherapy	9
Histology specific radiotherapy.....	10
Proton therapy.....	10
2. Introduction	11
3. Scientific basis Indications	12
Timing and interval.....	16
Dose and fractionation	18
Target definition	20
Technique	21
Site specific radiotherapy	23
Histology specific radiotherapy.....	26
Proton therapy.....	28
4. References.....	29

5. Method	38
6. Monitoring	41
7. Appendices	42
Appendix 1 – Search protocol	42
Appendix 2 – Links to international radiotherapy soft tissue sarcoma guidelines	42
Appendix 5 – Evidence table.....	66
Appendix 6 - What's New - (Old change log)	91
8. About this clinical guideline	92

1. Anbefalinger – Dansk (Quick guide)

Indikationer

1. Radioterapi kombineret med ekstremitets bevarende kirurgi med vid eller marginal margin er standard behandling af lokaliserede dybt liggende højmalignt sarkomer (A)
2. Radioterapi bør udelades efter operation med vid eller marginal margin i lavmalignt sarkomer (A)
3. Radioterapi bør udelades efter operation med vid margin i overfladiske (subkutane) sarkomer uanset grad; dog kan postoperative radioterapi overvejes hvis margin er < 5mm efter fjernelse af et højmalignt overfladisk bløddelssarkom (B)
4. Radioterapi er ikke en erstatning for genoperation i højmalignt sarkomer med positiv (intralesional) margin (B), men kan brugs for lavmalignt sarkom (B)
5. Udvalgte dybdeliggende sarkom særlig dem der er under 5 cm i diameter kan behandles alene med kirurgi, hvis marginen var >1 cm (B)
6. Radikal strålebehandling bør overvejes til radikal behandling i kliniske situationer, hvor ingen acceptabel kirurgisk behandling er tilgængelig (B)

Timing og interval

7. Radioterapi kan gives enten præ- eller post- operativt (A)
8. Hvis re-eksicion er planlagt, kan radioterapi gives enten præ- eller postoperativt (B)
9. Ved præoperativ strålebehandling, skal det ikke tilføjes en boost efter operationen, hvis marginerne var marginale eller intralæsionelt (B)
10. I tilfælde af positiv margin efter præoperativ stråleterapi kan yderligere onkologisk behandling vurderes i henhold til den estimerede risiko for recidiv (MS)
11. Det optimale interval mellem kirurgi og strålebehandling (enten præ- eller post-operativt) er 3-6 uger (A)

12. Den maksimale forsinkelse tilladt før den postoperative strålebehandling er 4 måneder (B)

Dosis og fraktionering

13. Patienter, der modtager præoperativ stråleterapi, bør behandles med 50 Gy i 2 Gy / fraktion som standard præoperativ dosis (A)
14. Patienter, der modtager postoperativ stråleterapi, bør behandles med en minimumsdosis på 50 Gy i 2 Gy / fraktion + A boost til tumorlejet op til 66 Gy afhængige af den kirurgiske margenstatus (B)
15. Patienter, der behandles med radikal-intenderet strålebehandling, bør behandles med 68-74 Gy givet med 1,8 - 2,0 Gy daglige fraktioner (B)
16. Alternativ fraktionering (accelererede, hypofraktionerede eller accelererede hyperfraktionerede regimer) er ikke standard, men kan anvendes i udvalgte tilfælde, herunder til radiosensitive STS subtyper (myksoid liposarkom) (B)

Target definition

17. Target for præoperativ strålebehandling bør afgrænses som følger: 1) Gross target volumen (GTV) defineres ved hjælp af T1-vægtet MR med kontrast. 2) kliniske target volumen (CTV) er konstrueret ved at udvide GTV 3,5 - 4 cm i længderetningen og 1,5 cm lateralt og forfra-bagfra retning. CTV bør omfatte peritumeralt ødem på T2-vægtede scanninger, men bør ikke udvides ud over overfladen af de tilstødende knogler og fasciae, medmindre disse strukturer er involverede (A)
18. Target for postoperativ strålebehandling bør afgrænses som følger: 1) CTV'en forlænges i alle retninger med 1,5 cm, undtagen i længderetningen, hvor udvidelsen er 4 cm. Radialt bør det elektive CTV omfatte arret og enhver postoperativ væskeopsamling, men behøver ikke udvides længere end huden og overfladen af de tilstødende knogler, fasciae og leddene, medmindre disse strukturer er involveret. 2) Boostet er det samme volumen som det elektive CTV, undtagen i længderetningen, hvor det er defineret af den rekonstruerede GTV plus en 2 cm-margin (A)
19. Target for radikal strålebehandling bør defineres som følgende: 1) GTV defineres af den T1-vægtede MR med kontrast. 2) CTV er konstrueret ved at udvide GTV 3,5-4 cm

i længderetningen og 1,5 cm lateralt og forfra-bagfra retningr. CTV bør omfatte peritumoralt ødem på T2-vejede scanninger, men bør ikke udvides ud over overfladen af de tilstødende knogler og fasciae, medmindre disse strukturer er involveret. 3) Boost CTV er GTV plus en 2 cm margen i længdeplanet, men den radiale margen er 0,5 -1,0 cm (A)

Teknik

20. Sarkompatienter bør behandles med intensitetsmoduleret strålebehandling (IMRT) teknik, mens billedstyret radioterapi (IGRT) teknik anbefales, når den er muligt og relevant (B)
21. Ved planlægning af præ- eller postoperative radioterapi mod underekstremiteten skal normalvævsconstraints for vægtbærende knogler anvendes, såfremt dette er muligt uden at gå på kompromis med targetdækning (B)

Site-specifik strålebehandling

22. For retroperitoneal og intra-abdominal sarkomer, kirurgi er standardbehandling (A)
23. For retroperitoneale og intra-abdominale sarkomer, bør præoperativ stråleterapi overvejes hos patienter med liposarkom og lav grade sarkom (b), mens både adjuverende strålebehandling (50 Gy i \pm boost op til 10 Gy) og radikal strålebehandling (≥ 60 Gy) kan overvejes i udvalgte tilfælde (C)
24. For uterin sarkomer, kirurgi er standardbehandling (A)
25. For uterin sarkomer, kan adjuverende strålebehandling (50-60 Gy) overvejes i udvalgte tilfælde (B)
26. Standardbehandling for hoved og hals sarkomer er kirurgi + postoperativ stråleterapi (60-66 Gy), men præoperativ strålebehandling kan overvejes til individuelle patienter (B)
27. Radioterapi bør overvejes i højmalignt bryst sarkompatienter der opereres med marginal margin og hos patienter med intralesionale marginer, hvis der ikke kan udføres re-eksicision (B)

Histologisk specifik strålebehandling

28. Patienter med myxoid liposarcoma (MLS), uafhængig af gradering, skal diskuteres med henblik på præoperativ radioterapi, da denne subtype er mere radiosensitiv end andre bløddelssarkomer (B)
29. Patienter med rhabdomyosarcoma bør behandles i overensstemmelse med resultaterne af den seneste europæiske rhabdomyosarkom protokol (EpSSG, FAR-RMS) som beskrevet i bilag 3 (A)

Proton behandling

30. Børn og unge voksne patienter, der modtager højdosis radioterapi til bløddel sarkom på kritiske steder som hoved og hals, paraspinal region, bækken og bases cranii bør overvejes for Proton-terapi (B)

Recommendations English (Quick guide)

Indications

1. Radiotherapy combined with limb sparing surgery with wide or marginal margin is treatment of choice for localized deep seated high grade sarcomas (A)
2. Radiotherapy is omitted after surgery with wide or marginal margin in low grade sarcomas (A)
3. Radiotherapy is omitted after surgery with wide margin in superficial (subcutaneous) sarcomas regardless of grade, but can be considered if the margin is <5mm in a high grade superficial sarcoma (B)
4. Radiotherapy is not a substitute for re-excision in high grade sarcomas with positive (intralesional) margin (B) but optional for low-grade sarcomas (B)
5. Selected small deep seated intermediate/high grade sarcomas particularly those tumours $\leq 5\text{cm}$ in diameter could be treated with surgery alone if the margin was wider than 1cm (B)
6. Radical radiotherapy should be considered for radical treatment in clinical situations where no acceptable surgical option is available (B)

Timing and interval

7. Radiotherapy can be given either pre op post operatively (A)
8. If re-excision is planned, radiotherapy can be planned either pre or postoperatively (B)
9. If preoperative radiotherapy is used, do not add boost after surgery if the margins were marginal or positive (B)
10. In case of positive margin after preoperative radiotherapy additional oncologic treatment could be considered according to the estimated risk of recurrence (MS)
11. The optimal interval between surgery and radiotherapy (whether pre or postoperative) is 3-6 weeks (A)

12. The maximum delay allowed for the post-operative radiotherapy is 4 months (B)

Dose and fractionation

13. Patients receiving preoperative radiotherapy should be treated with 50 Gy in 2 Gy/fraction as the standard preoperative dose (A)
14. Patients receiving postoperative radiotherapy should be treated with a minimum dose of 50 Gy in 2 Gy/ fraction + a boost to the tumour bed up to 66 Gy according to the surgical margin status (B)
15. Patients treated with definitive radiotherapy should receive a dose of 68-74 Gy given with 1.8 - 2.0 Gy daily fractions (B)
16. Alternative fractionation (e.g. accelerated, hypofractionated or accelerated hyperfractionated regimens) is not standard but can be used in selected cases, e.g. radiosensitive histological subtypes (myxoid liposarcoma) (B)

Target definition

17. Target for preoperative radiotherapy should be delineated as following: 1) The gross tumour volume (GTV) is defined using gadolinium-enhanced, T1-weighted MRI, 2) The clinical target volume (CTV) is constructed by expanding the GTV 3.5 – 4 cm longitudinally and 1.5 cm laterally and antero-posteriorly. CTV should include peritumoral edema on T2-weighted scans but should not be expanded beyond the surface of the adjacent bones and fasciae, unless these structures are involved (A)
18. Target for postoperative radiotherapy should be delineated as following: 1) The CTV is extended in all directions by 1.5 cm, except longitudinally, where the expansion is 4 cm. Radially, the elective CTV should include the scar and any postoperative fluid collection but does not need to be expanded further than the skin and the surface of the adjacent bones, fasciae, and joints, unless these structures are involved. 2) The boost is the same volume as the elective CTV, except in the longitudinal direction, where it is defined by the reconstructed GTV, plus a 2 cm margin (A)
19. Target for radical radiotherapy should be delineated as following: 1) The GTV is defined by the gadolinium-enhanced, T1-weighted MRI, 2) The clinical target volume (CTV) is constructed by expanding the GTV 3.5 – 4 cm longitudinally and

1.5 cm laterally and antero-posteriorly. CTV should include peritumoral edema on T2-weighted scans but should not be expanded beyond the surface of the adjacent bones and fasciae, unless these structures are involved. 3) The boost CTV is the GTV plus a 2 cm margin in the longitudinal plane, but the radial margin is 0.5 -1.0 cm (A)

Technique

- 20. Sarcoma patients should be treated with intensity modulated radiotherapy (IMRT) technique and image guided radiotherapy (IGRT) technique is recommended when feasible and relevant (B)
- 21. Planning dose constraints for weight bearing bones should be used when planning pre-or postoperative radiotherapy to the lower extremity (B), if achievable without target dose compromise

Site specific radiotherapy

- 22. Standard treatment for retroperitoneal and intra-abdominal sarcomas is surgery alone (A)
- 23. For retroperitoneal and intra-abdominal sarcomas, preoperative radiotherapy should be considered in patients with liposarcoma or low grade sarcomas (B) while adjuvant radiotherapy (50 Gy in \pm a boost of up to 10 Gy), or radical radiotherapy (\geq 60 Gy) can be considered in selected cases (C)
- 24. Standard treatment for uterine sarcomas is surgery alone (A)
- 25. For uterine sarcomas, adjuvant radiotherapy (50-60 Gy) can be considered in selected cases (B)
- 26. Standard treatment for head and neck STS is surgery + post-operative radiotherapy (60 -66 Gy) but preoperative radiotherapy can be considered for individual patients (B)
- 27. Radiotherapy should be considered in high grade breast sarcoma patients operated with marginal margin and in patients with intralesional margins if re-excision cannot be performed (B)

Histology specific radiotherapy

- 28. Patients with myxoid liposarcoma (MLS), regardless of grade, should be considered for preoperative radiotherapy due to the unique radiosensitivity of this STS subtype (B)**
- 29. Patients with rhabdomyosarcoma should be treated according to the results of the most recent European rhabdomyosarcoma protocol (EpSSG, FAR-RMS) as detailed in appendix 3 (A)**

Proton therapy

- 30. Children and young adult patients receiving high dose radiotherapy for soft tissue sarcomas in critical sites such as the head and neck, paraspinal region, pelvis and base of skull should be considered for Proton therapy (B)**

2. Introduction

Surgery using amputation has always been the main line of treatment for localized soft tissue sarcoma (SST) yielding local control rates of >80%(1). Some non-randomized (2) and an early single randomized study (3) showed that limb-sparing surgery (LSS) + post-operative radiotherapy is as effective as amputation in terms of local control and survival. Thus, establishing this treatment as the golden standard of localized SST in the last 3 decades. The challenge in sarcomas is their rarity and distribution between various histological subtypes and anatomical localizations. Most of the studies and randomized trials in sarcomas are being done in the trunk and extremities. The experiences gained in these sites are being extrapolated for treating sarcomas in other sites and the practice is later confirmed by various retrospective and single institution studies.

This guideline examines the evidence that has been accumulated regarding the role of external beam radiotherapy in treating sarcomas. The recommendations are based on the expected effect on local control rate and possibly overall survival.

Objective

The overall objective of this guideline is to support high-quality cancer care across the Danish healthcare system.

The specific objective is to describe the details of applying radiotherapy in patients with localized soft tissue sarcomas. These details include indications, timing and interval, dose and fractionation, target definition, techniques, site specific and histology specific radiotherapy as well as the evidence of using proton therapy. The guideline is also concerned with specifying the various subgroups in which radiotherapy could/should be omitted.

Patient population

All adult patients with localized soft tissue sarcoma are treated with radical intent regardless of grade and anatomical site.

Target users

This guideline is primarily developed to support clinical decision-making and quality improvement. The target users are healthcare professionals working in Danish cancer care.

3. Scientific basis

Indications

1. **Radiotherapy combined with limb sparing surgery with wide or marginal margin is treatment of choice for localized deep seated high grade sarcomas (A)**
2. **Radiotherapy is omitted after surgery with wide or marginal margin in low grade sarcomas (A)**
3. **Radiotherapy is omitted after surgery with wide margin in superficial (subcutaneous) sarcomas regardless of grade but can be considered if the margin is <5mm in a high grade superficial sarcoma (B)**
4. **Radiotherapy is not a substitute for re-excision in high grade sarcomas with positive (intralesional) margin (B) but optional for low-grade sarcomas (B)**
5. **Selected small deep seated intermediate/high grade sarcomas particularly those tumours $\leq 5\text{cm}$ in diameter could be treated with surgery alone if the margin was wider than 1cm (B)**
6. **Radical radiotherapy should be considered for radical treatment in clinical situations where no acceptable surgical option is available (B)**

Literature and evidence review

Deep-seated high-grade sarcomas

The evidence for the indication of radiotherapy in deep-seated high-grade sarcomas comes from two randomized studies (4, 5) [1b] with two subsequent long term follow up publications (6, 7) [1b] showing that limited limb sparing surgery combined with adjuvant radiotherapy is superior to surgery alone. One of these two trials used adjuvant external beam radiotherapy (141 patients) and the other used adjuvant brachytherapy (164 patients). In both trials combined therapy significantly increased local control rate for high grade but not for low grade sarcomas. Moreover, both trials showed no increases in the overall survival rate.

Further evidence is derived from two major retrospective studies (8, 9) [2b, 2c]. The first is a French study on 3255 soft tissue sarcoma patients showing that adjuvant radiotherapy was associated with a significant benefit in terms of local relapse-free survival despite a higher incidence of competing deaths in patients managed with adjuvant radiotherapy compared to patients not receiving radiotherapy (8) [2b]. The other large study was a Scandinavian database analysis of adjuvant radiotherapy in 1093 adult patients with extremity or trunk wall soft tissue sarcoma treated in the period 1986–2005. The study confirmed that adjuvant radiotherapy reduced the risk of local recurrence in soft tissue sarcoma, irrespective of the tumor depth, malignancy grade, and surgical margin status (9) [2c]. The most evident reduction however was in deep-seated high-grade sarcomas.

The local control results are summarized in Table 1.

		Without RT (n=622)	RT (n=453)
Subcutaneous, low-grade	Wide margin	0.97	0.99
	Marginal margin	0.97	0.99
	Intralesional margin	0.82	0.93
Subcutaneous, high-grade	Wide margin	0.86	0.95
	Marginal margin	0.67	0.87
	Intralesional margin	0.38	0.71
Deep, low-grade	Wide margin	0.96	0.98
	Marginal margin	0.89	0.96
	Intralesional margin	0.75	0.90
Deep, high-grade	Wide margin	0.80	0.93
	Marginal margin	0.57	0.82
	Intralesional margin	0.26	0.62

Table 1a. 5-year local control rates by prognostic group and radiotherapy in 1093 patients with extremity and trunk wall soft tissue sarcoma (9). Red colour denotes statistical significance, blue is borderline significance, and black is no significance.

Table III. Local recurrence-free survival according to use of radiotherapy.

Groups by tumour size and grade	Adjuvant RT-			Adjuvant RT+			p-value*
	n	5-yr, %	10-yr, %	n	5-yr, %	10-yr, %	
Group 1: ≤ 5 cm, low grade	18	93	83	1	100	100	0.673
Group 2: ≤ 5 cm, high grade	32	82	82	58	96	96	0.019
Group 3: > 5 cm, low grade	12	100	83	2	100	100	0.564
Group 4: > 5 cm, high grade	32	73	66	149	87	78	0.027

*Log-rank test.
RT, radiotherapy.

Table 1b: Local recurrence-free survival according to use of radiotherapy stratified according to tumour size in superficial soft tissue sarcoma(10).

Based on Yang et al. og Beane et al. (3, 5)[1b], as well as the most recent European School of Medical Oncology (ESMO) guidelines(11), and other reviews(12), the strength of the recommendation for radiotherapy of deep seated high-grade sarcomas is evaluated to be strength A.

Low grade sarcomas

The same prospective and retrospective studies had a subgroup of low grade sarcomas and their analysis showed that radiotherapy could be safely omitted for low grade sarcomas operated wide or marginal margin surgery as both local control rates and long term overall survival after surgery alone are excellent (4-7) [1b], (8)[2c], (9)[2c].

Based on the prospective trials (4-7) [1b], the 2 large retrospective analyses (8) [2c], (9)[2c] as well as the most recent ESMO guidelines(11), the strength of the recommendation for radiotherapy of deep seated low-grade sarcomas is estimated to be strength A.

Superficial (subcutaneous) sarcomas

There is no randomized trial studying radiotherapy in superficial (subcutaneous) sarcomas. The evidence regarding the indication for radiotherapy in this disease category was derived from 4 retrospective studies (9, 12, 13) (10)[2c].

The first comprised 129 patients with subcutaneous sarcoma diagnosed between 1964-1985 in Sweden, and showed that only 7% of the high-grade tumours recurred locally after wide local excision without radiotherapy (12) [2c]. The second study reported results from 622 consecutive, surgically treated superficial soft tissue sarcoma patients that were treated with surgery and selective radiotherapy. The incidence of local recurrence and metastasis was 9% and 12%, respectively. Factors that affected survival and local recurrence were tumor size, age and tumour grade. Clear surgical margins were correlated to lower risk for local recurrence and selected patients benefited from adjuvant radiotherapy. The authors concluded that surgery with adequate surgical margins is adequate, whereas radiotherapy has a secondary role and may be used in selected patients (13) [2b]. The third study is the Scandinavian database study mentioned earlier (9) [2c] and summarized in Table 1. It confirmed that surgery with a wide margin alone is optimal treatment enough for superficial sarcomas with a 86% 5-year local control rate. The study showed however that surgery alone is not satisfactory if the margins were less than wide and confirmed the value of adjuvant radiotherapy in improving local control rate in these cases. The latest study is a retrospective cohort of 300 patients with superficial STS. Local recurrence-free survival was significantly better in high grade tumours regardless of size, for close margins (<5mm)(10). Especially in superficial tumours with histologies with infiltrative growth, such as myxofibrosarcoma, radiotherapy can reduce the risk of relapse (14) based on retrospective evidence.

Based on the retrospective studies (9) [2c], (10, 12, 13) [2b], and other reviews (15-17) [2b] the recommendation for radiotherapy of superficial sarcomas is estimated to be strength B.

Intralesional margin

The evidence for the indication of radiotherapy following surgery yielding intralesional margin is derived from the large database Scandinavian study (9) [2c] and a retrospective study of 110 adult patients with primary high-grade extremity STS who underwent limb sparing surgery and were found to have a histologically positive microscopic surgical margin (18) [2b]. In both studies radiotherapy significantly improved the local control rate compared to the no radiotherapy group. The local control however was inferior to that achieved in patients with wide or marginal margin (19) [2b]. Radiotherapy can't be considered a substitute for re-excision in positive margin (intralesional excision) high grade sarcomas.

The evidence based on these 2 studies (9) [2c], (19)[2b] and ESMO guidelines (11) [2c] is considered to be strength B.

Radiotherapy also improved local control for low grade sarcomas after inadequate surgery. This was shown in the large Scandinavian database study (9) [2c] as well as in a small retrospective analysis of 132 patients with low grade sarcomas (20) [2b]. Radiotherapy however is associated with known late effects (21) [2b]. The low risk of metastasis means that the decision to give radiotherapy has to be weighed against late effects of radiotherapy.

The evidence based on these 2 studies (9) [2c], (20)[2b] is considered to be strength B.

T1 (< 5 cm) deep seated intermediate/high grade sarcomas

The evidence for radiotherapy in this subgroup comes from 3 studies (22-24) [2b,2c,2b]. The first study describe a long term follow up study of a prospective trial testing surgery alone in 88 patients with STS of trunk and extremities. Subgroup analysis of patients with small tumours (T1) and R0 resection showed a cumulative incidence rates of local recurrence at 5 and 10 years of 7.9% and 10.6%, respectively; and a 5- and 10-year sarcoma-specific death rates of 3.2% and 3.2% (18) [2b]. The second study was a large SEER database study of 983 patients showing better survival for patients with sarcomas >5cm in diameter receiving adjuvant radiotherapy but no survival difference for patients with tumours < 5cm (19) [2c]. The third study describe a retrospective analysis of 204 patients with small (≤5cm) STS tumours of the extremities where 88 received post operative radiotherapy using brachytherapy technique and 116 did not. There was no difference in local control or survival between the two groups (20) [2b].

The evidence based on these 3 studies (23) [2b], (24)[2c], (24)[2b] is considered to be strength B.

Radical radiotherapy

In case of inoperable sarcomas, the use of radical radiotherapy was tested in many retrospective studies using photons or proton therapy. The various studies have consistently showed local control rates of 25-53% depending on the tumour size and grade (22, 25, 26) [2b].

Based on these 2 retrospective studies (25, 27) [2b] and ESMO guidelines (11) [2c] the strength of evidence for the use of radical radiotherapy in inoperable sarcomas is considered to be strength B. As there can never be a study randomizing between radiotherapy and no treatment it is considered a standard of care.

Patient values and preferences

In case of sarcomas in the extremities, the historical alternative to this recommendation is amputation. We assume that the majority of patients would prefer a limb preserving surgery and radiotherapy over amputation.

Rationale

The outcome that forms the basis of the recommendation is local control, limb preservation, better limb function and a good quality of life. The current recommendation does not only preserve the limb but also a good function. This is balanced against amputation (in case of extremity sarcoma) or major mutilating surgery in case of sarcoma to other sites.

Timing and interval

7. **Radiotherapy can be given either pre op post operatively (A)**
8. **If re-excision is planned, radiotherapy can be planned either pre or postoperatively (B)**
9. **If preoperative radiotherapy is used, do not add boost after surgery if the margins were marginal or positive (B)**
10. **In case of positive margin after preoperative radiotherapy additional oncologic treatment could be considered according to the estimated risk of recurrence (MS)**
11. **The optimal interval between surgery and radiotherapy (whether pre or postoperative) is 3-6 weeks (A)**
12. **The maximum delay allowed for the post-operative radiotherapy is 4 months (B)**

Literature and evidence review

Pre or postoperative radiotherapy

The best evidence regarding treatment sequencing comes from the Canadian Sarcoma Group's SR2 randomized trial of pre- vs postoperative radiation (28) [1b]. This trial randomly assigned patients with localized primary or recurrent extremity sarcomas to be treated using external-beam radiation (50 Gy with a 16 Gy boost for microscopically positive surgical margins) followed by surgery, or surgery followed by external-beam radiation (66 Gy). This trial with its later long term follow up results (29, 30) [1b] in addition to meta-analysis (31) [2c] and one retrospective study (32) [2b] confirmed that preoperative RT was equivalent to postoperative RT regarding local control and long-term physical function. A systematic review and meta-analysis analysing six studies ($n = 4192$ patients) found a statistically significant advantage in post-operative radiotherapy for overall survival (HR 1.15 and $p = 0.05$). Combined HRs for disease-free (1.25 and $p = 0.22$) and disease-specific (1.06 and $p = 0.43$) survival also favoured post-operative radiotherapy but did not achieve statistical significance. Preoperative radiotherapy came with a statistically significant higher risk of wound complications(33). ASTRO guidelines still recommends preoperative over postoperative RT in most patients(34).

Sequencing radiotherapy when re-resection is planned was tested in one retrospective study of 249 patients in whom re-excision was planned. The study showed that there was no evidence that radiotherapy sequence influenced local control, metastatic control, disease-free survival, or disease-specific survival between the pre and the postoperative radiotherapy groups (35) [2b].

Based on the prospective trial results (28-30) [1b], that was confirmed by meta-analysis (31) [2c] and retrospective data (32) [2b] and in accordance with the most recent ESMO guidelines (11) the strength of the recommendation for the timing of radiotherapy is evaluated to be strength A.

Value of boost after preoperative radiotherapy

Marginal margin after preoperative radiotherapy doesn't compromise local control (36) [2b]. In an attempt to study the value of postoperative boost for patients receiving preoperative radiotherapy, a retrospective study evaluated patients who received preoperative radiotherapy (n = 49) and patients who received preoperative radiotherapy with a postoperative boost (n = 45). There were no differences in the proportion or rate of local recurrence, distant metastasis or death due to sarcoma between the two groups (37) [2b]. Another retrospective study in 216 patients showed that to be true even if the surgical margin was positive (38) [2b].

Based on the 3 retrospective studies (36-38) [2b], the strength of the recommendation for the boost following preoperative radiotherapy of deep seated high-grade sarcomas is evaluated to be strength B.

Interval

The Canadian prospective randomized study planned surgery 3-6 weeks after the end of preoperative radiotherapy (28) [1b]. The time interval between surgery and postoperative radiotherapy is usually the same (3-6 weeks). Data on the effect of prolonged interval caused by, for example, infection was gathered from 4 studies (39-42). The largest was a database retrospective French study in more than 1000 patients. There was no effect on local control rate or survival of prolonged time up to 4 months between surgery and start of adjuvant radiotherapy (40) [2b]. The same results were seen in 2 other retrospective studies (39, 41) [2b]. The fourth and last retrospective study in 100 patients showed that more than 4 months delay lead to inferior local control rates (42) [2b].

Based on the 4 retrospective studies (39-42) [2b], the strength of the recommendation for the interval between surgery and radiotherapy of deep seated high-grade sarcomas is estimated to be strength B.

Patient values and preferences

Radiation-associated wound complications rate in patients receiving preoperative radiation was about 33% vs 16% in the postoperative radiation arm (28). However, the late tissue effects including fibrosis and edema were more common following postoperative radiation (31, 32). These effects are irreversible and were probably related to the higher radiation dose and larger field size required for postoperative radiation.

Rationale

Tumour regression after preoperative radiotherapy is limited. Preoperative radiotherapy can't be aimed at rendering an inoperable tumour, operable.

Dose and fractionation

- 13. Patients receiving preoperative radiotherapy should be treated with 50 Gy in 2 Gy/fraction as the standard preoperative dose (A)**
- 14. Patients receiving postoperative radiotherapy should be treated with a minimum dose of 50 Gy in 2 Gy/ fraction + a boost to the tumour bed up to 66 Gy according to the surgical margin status (B)**
- 15. Patients treated with definitive radiotherapy should receive a dose of 68-74 Gy given with 1.8 - 2.0 Gy daily fractions (B)**
- 16. Alternative fractionation (e.g. accelerated, hypofractionated or accelerated hyperfractionated regimens) is not standard but can be used in selected cases, e.g. radiosensitive histological subtypes (myxoid liposarcoma) (B)**

Literature and evidence review

The preoperative dose

The evidence for the current preoperative standard dose of 50Gy in 2 Gy/fx lies in the Canadian prospective study comparing pre vs. postoperative radiotherapy (28) [1b]. In this study the experimental arm was the preoperative radiotherapy and the study proved that 50 Gy is as effective the more established postoperative dose of 60-66 Gy. There are no prospective studies comparing various preoperative doses.

Based on this trial by O'sullivan et al. (28)[1b] and various international guidelines (11, 43-45) [2c,1a-1a] the evidence for the preoperative dose is considered to be strength A.

The postoperative dose

The evidence for the current practice of delivering a dose of 60-66 Gy in the postoperative setting could be traced to an old retrospective study from MD Anderson in which the data of 465 sarcoma patients receiving either pre or postoperative radiotherapy was analysed. The postoperative dose ranged from 50 to 65 Gy and the data suggested that 50 Gy postoperative is probably not adequate for proper local control (46) [2b]. Contrary results were seen in some more recent retrospective studies from Scandinavian centres (47) [2b] and from France (48) [2b] showing that post-operative radiation dose of 50 Gy may lead to the same local control rates as other studies delivering higher doses. An explanation to the different results may be in applying strict patient selection criteria and using modern surgical techniques in specialized sarcoma centres.

The only prospective clinical trial on which our current postoperative practice is built was done in 91 patients randomized between 2 arms. Patients in the postoperative radiotherapy arm received 63 Gy to tumour bed and 45 Gy to wider margin (5) [1b].

A large retrospective study in 775 patients with high risk of local recurrence after gross total resection showed that patients with high risk of local recurrence benefited a radiotherapy dose of 64-68 Gy compared to 60 Gy

(49) [2b]. The same tendency was described in 2 small earlier retrospective studies (50, 51) [2b]. [A more recent study in 154 patients with positive surgical margin confirmed by multivariate analysis that patients who received doses > 64 Gy had better local control rates (52) [2b].

Based on the only prospective study (5) [1b] and the various retrospective data (46-49) [2b] as well as the various current guidelines (43-45) [1a] the strength of the evidence for the current postoperative dose (50 Gy + risk adapted boost to 66 Gy) is considered to be strength B.

Radical radiotherapy

The evidence for the radical radiotherapy dose is derived from the above mentioned retrospective studies (49-52) [2b] describing a dose-response relationship between the total dose and local control. This relationship suggests that high radiation doses are needed for large inoperable tumours. In radical radiotherapy for inoperable tumours, a standard radiotherapy practice is to deliver doses > 66 Gy leading to a local control rate of 25-50% depending on tumour type and risk factors (25, 27) [2b].

The strength of evidence for the dose for radical radiotherapy in inoperable sarcomas based on these retrospective studies is estimated to be strength B.

Alternative fractionation

Various alternative fractionation (accelerated, hypo-fractionation, hyper-fractionation or split course) were tested in various trials or small single institutions retrospective studies (53-58) [2b]. All studies claimed equal results with standard fractionation. The number of publications is increasing, and a prospective single institution study has been published applying preoperative hypofractionated radiotherapy of 6 Gy x 5, 5 fractions per week in 50 patients, confirming acceptable toxicity and good local control, with a follow-up of 2 years(59). For myxoid liposarcoma (MLS), there are prospective, non-randomized data establishing the efficacy of a short course preoperative radiotherapy to a total dose of 36 Gy in 2 Gy fractions(60). Real world data are currently being collected by an international working group.

Still, hypofractionation cannot be routinely recommended outside clinical trials [B]. Short-course preoperative radiotherapy can be safely used in MLS [B].

Patient values and preferences

Hypo-fractionation could be preferred by some patients, especially frail elderly patients, as the overall treatment time is shorter but the risk of late effects is higher. The value of alternative fractionation should be weighed against possible risks after discussion with patient.

Rationale

The current practice and recommendation provide effective local control and an acceptable risk of acute and late effects. Hypo-fractionation may increase late effects while hyper-fractionation is associated with more

acute toxicities. In both cases the biological tumour dose should not be compromised. Therefore alternative fractionation other than for patients with MLS is only recommended within clinical trials.

Target definition

17. Target for preoperative radiotherapy should be delineated as following: 1) The gross tumour volume (GTV) is defined using gadolinium-enhanced, T1-weighted MRI, 2) The clinical target volume (CTV) is constructed by expanding the GTV 3.5 – 4 cm longitudinally and 1.5 cm laterally and antero-posteriorly. CTV should include peritumoral edema on T2-weighted scans but should not be expanded beyond the surface of the adjacent bones and fasciae, unless these structures are involved (A)
18. Target for postoperative radiotherapy should be delineated as following: 1) The CTV is extended in all directions by 1.5 cm, except longitudinally, where the expansion is 4 cm. Radially, the elective CTV should include the scar and any postoperative fluid collection but does not need to be expanded further than the skin and the surface of the adjacent bones, fasciae, and joints, unless these structures are involved. 2) The boost is the same volume as the elective CTV, except in the longitudinal direction, where it is defined by the reconstructed GTV, plus a 2 cm margin (A)
19. Target for radical radiotherapy should be delineated as following: 1) The GTV is defined by the gadolinium-enhanced, T1-weighted MRI, 2) The clinical target volume (CTV) is constructed by expanding the GTV 3.5 – 4 cm longitudinally and 1.5 cm laterally and antero-posteriorly. CTV should include peritumoral edema on T2-weighted scans but should not be expanded beyond the surface of the adjacent bones and fasciae, unless these structures are involved. 3) The boost CTV is the GTV plus a 2 cm margin in the longitudinal plane, but the radial margin is 0.5 -1.0 cm (A)

Literature and evidence review

Detailed recommendations for radiotherapy definition for dose planning are missing in the majority of the published data. Old retrospective data on postoperative radiotherapy suggest cranio-caudal margin that is at least 5 cm and < 10 cm (61) [2b]. The evidence for standard target definition in this guideline was based on the NCIC prospective trial comparing pre- and postoperative external beam radiotherapy (28) [1b]. This target definition practice is supported by the optimal local control of 92% in one retrospective study of 56 patients adopting the same guidelines (62) [2b] compared to slightly lower control rate (88%) in another retrospective study using smaller margins (63) [2b]. Even with advanced delivery methods and daily image guidance, an increased risk of marginal miss and local recurrence was found when using smaller margins(64). Including the

postoperative fluid collection in adjuvant radiotherapy is based on one retrospective study of 88 patients of sarcoma in the trunk wall and extremities who received postoperative radiotherapy. The postoperative fluid collection was included in the majority of the patients. After a median follow-up of 4.3 years, patients with and without fluid collection had 5-year local control rates of 77.7% and 90.8% ($P = 0.105$). Eight patients with fluid collection had local recurrence, of which six patients had recurrent tumours at or within 4 cm of the collection wall suggesting that it could be a risk factor for recurrence (65) [3b].

Various consensus papers and guidelines confirmed the use of the same target for preoperative and postoperative radiotherapy (45, 66-68).

Target definition for radical radiotherapy of sarcomas in the trunk and extremities is similar to the preoperative radiotherapy to the 50Gy volume. The boost to the higher dose is similar in concept to the postoperative boost. However smaller margin to CTV may be needed since the total dose is higher as described in the Scandinavian sarcoma group guidelines (45) and the last rhabdomyosarcoma and non-rhabdomyosarcomas EpSSG protocols that also included adult patients (appendix 3).

Based on the cumulative data from 1 prospective study (25) [1b] and 3 retrospective studies (61-63) [2b), (65)[3b] as well as various guidelines (45) and current protocols describing best standard practice, the strength of evidence for target definition could be considered as strength A.

Patient values and preferences

Not relevant.

Rationale

The current standard practice and recommendations allows for optimal coverage of tumour volume and areas at risk of microscopic disease to reduce the risk of local recurrence and adapt the clinical target volume to the anatomical site and allows for smaller target in areas such as the head and neck.

Technique

- 20. Sarcoma patients should be treated with intensity modulated radiotherapy (IMRT) technique and image guided radiotherapy (IGRT) technique is recommended when feasible and relevant (B)**
- 21. Planning dose constraints for weight bearing bones should be used when planning pre-or postoperative radiotherapy to the lower extremity (B), if achievable without target dose compromise**

Literature and evidence review

The evidence in this guideline was based on 10 small single-arm and retrospective studies (69-78) [2b,3b, 3b, 2b, 3b, 2b, 2b, 3b] confirming the values of the new technique in line with what is to be expected based on the new technological advancement.

IMRT has been evaluated prospectively in 18 patients and showed that it reduced the severity and incidence of wound healing complications through sparing the uninvolved tissues (74) [3b]. Other reports showed that the better sparing of normal tissue (69, 70, 73) [3b,3b,2b] when IMRT was used was associated with better target coverage (76) [3b], and significantly reduced local recurrence compared with conventional external beam therapy (72) [2b]. One study showed that image guided radiotherapy (IGRT) technique significantly reduced late toxicities after preoperative radiotherapy without increasing marginal-field recurrences (72) [2b]. Another study showed that IGIMRT reduced wound complication below expected values and significantly diminished the need for tissue transfer (77) [2b]. In one non-randomized study local control with IMRT was significantly better than brachytherapy despite higher rates of adverse features in the IMRT cohort (75) [3b].

Intensity modulated radiotherapy (IMRT) is a technologically advanced techniques allowing for better dose conformity in tumour target and lower doses to organs at risk. Applying new and better technologies does not always require evidence from randomized clinical trials.

Based on the 10 retrospective studies [3b] that confirmed the value of IMRT, the strength of evidence is considered to be strength B.

The percentage of patients experiencing fracture of weight bearing bones after radiotherapy for STS is in contemporary datasets reported as between 1,8% and 6,7%, with a tendency towards lower number of fractures when using normal tissue constraints vs none(79, 80). Planning dose constraints for weight bearing bones in the lower extremity were suggested by Dickie et al. in 2009 based on retrospective analyses of fracture risk in patients that had received radiotherapy after surgery for soft tissue sarcoma. They concluded that the radiation-related fracture rates were lower when the mean radiation dose to the femur was < 37 Gy or when the maximum radiation dose anywhere along the length of the femur was < 59 Gy. Their investigation also shows that limiting the volume of femur that receives 40 Gy to less than 64% of the bone reduces the risk of fracture(81). Priority should be given to secure target coverage.

Patient values and preferences

Target coverage and normal tissue dose constraints as well as risk of acute and late toxicities have to be discussed with patients before start of radiotherapy. Patient values and preferences should be taken into consideration whenever planning radiotherapy for STS.

Rationale

IMRT technique seems to be able to spare normal tissues from excessive high dose of irradiation without compromising tumour target coverage with optimal radiation dose. Though never tested in prospective clinical

trial the current data agrees with the expected theoretical benefit and justifies its use as standard. It has been established that there is a dose response relationship in dose to weight bearing bones and risk of fracture. Though never tested prospectively the available data agrees with the expected theoretical benefit and justifies the use of normal tissue constraints, if target coverage still can be secured. These recommendations are in accordance to international guidelines (ASTRO soft tissue sarcoma guideline 2022).

Site specific radiotherapy

22. Standard treatment for retroperitoneal and intra-abdominal sarcomas is surgery alone (A)

23. For retroperitoneal and intra-abdominal sarcomas, preoperative radiotherapy should be considered in patients with liposarcoma or low grade sarcomas (B) while adjuvant radiotherapy (50 Gy in \pm a boost of up to 10 Gy), or radical radiotherapy (\geq 60 Gy) can be considered in selected cases (C)

Literature and evidence review

The evidence in this guideline is based on one large phase III randomized trial showing no value of adding preoperative radiotherapy (82) and many retrospective institution-based studies that reported improved local control following pre or post-operative radiotherapy but the numbers of patients are small and the results are conflicting and could be biased (25, 83-86) [2b,2b,2b2b,2b,3b,3b,2b].

The large phase III multicentre study was recently conducted by EORTC and randomized 266 patients between preoperative radiotherapy and surgery only (STRASS study). The median abdominal recurrence-free survival was 4.5 years (95% CI 3.9 to not estimable) in the radiotherapy plus surgery group and 5.0 years (3.4 to not estimable) in the surgery only group (hazard ratio 1.01, 95% CI 0.71-1.44; log rank $p=0.95$). There were no difference in side effects between the 2 groups and the final recommendations of the study was that Preoperative radiotherapy should not be considered as standard of care treatment for retroperitoneal sarcoma [1a]. In the subgroup analyses exploring patients with liposarcoma only, there was a 10% absolute abdominal recurrence-free survival benefit in favour of the radiotherapy plus surgery group (87) which suggest that preoperative radiotherapy might be considered in liposarcoma and in low-grade retroperitoneal sarcoma [2a]. However, these results should be regarded with caution because of the small number of patients and the possible impact of preoperative radiotherapy on the final histology, and the fact that these subgroup analyses were not preplanned(87).

One retrospective study reported a possible improved local control of radical radiotherapy to doses as high as 66 Gy (25) [3c] in inoperable retroperitoneal sarcomas. A population based study in over 2000 patients with non-retroperitoneal abdominal sarcomas, radiotherapy (adjuvant) seemed to improve survival (88) [3b] but the results should be regarded with caution since the majority of confounding factors could not be accounted for.

Based on one large randomized phase III study (87) one recommendation with estimated strength A was made and based on a subgroup analysis of the same study (87) another recommendation [2a] with strength B was made. Based on 5 retrospective studies (25, 83-86) [2b,2b2b,2b,3b,3b,2b] and one database study (88) [2c] that are suffering from possible selection and publication bias the strength of evidence regarding the role of radiotherapy in retroperitoneal and intraabdominal sarcomas is estimated to be strength B.

24. Standard treatment for uterine sarcomas is surgery alone (A)

25. For uterine sarcomas, adjuvant radiotherapy (50-60 Gy) can be considered in selected cases (B)

Literature review and evidence description

The evidence regarding the role of radiotherapy is derived from one randomized trial (89) [1b] and 10 [2c] retrospective studies [2b,2c-2c]. The results of the prospective study suffered from the fact that recruited only 224 patients in 13 years and included various sarcoma subtypes. Patients were randomized to either observation or pelvic radiation, 51 Gy in 28 fractions over 5 weeks. The analysis showed a significant reduction in local relapse ($p=0.004$) in the radiotherapy arm but no effect on survival or progression free survival. The majority of the reported retrospective studies showed favourable local control following postoperative pelvic radiotherapy of localised (stage II-IVA) high-grade uterine sarcoma (90-100) [2b,2c-2c]. The largest study analysed data from 2206 patients with non-metastatic uterine sarcoma treated with surgery with or without adjuvant radiotherapy (97) [2c]. Adjuvant radiotherapy was delivered as external beam radiation to the pelvis, with or without brachytherapy. The 5-year local recurrence free survival was 87%. Radiotherapy was one of the prognostic factors and was associated with improved local control compared with surgery alone ($p < 0.001$).

Based on the evidence from the prospective study of Reed NS et al. (89)[1b] and the various retrospective studies (90-94, 96-100) [2b], reviews (95) [2b] and international guidelines (45) [1a], the strength of evidence for the role of radiotherapy in uterine sarcomas is considered to be strength B.

26. Standard treatment for head and neck STS is surgery + post-operative radiotherapy (60 -66 Gy) but preoperative radiotherapy can be considered for individual patients (B)

Literature review and evidence description

It is generally recommended that STS situated in the head and neck (H&N) area be treated according to the same principles and protocols as other bone- and soft tissue sarcomas, depending on histological subtype (45) [1a]. Site-specific radiotherapy considerations regarding fixation and high precision small set-up margins (PTV = 3 - 5 mm) are common practice that is in accordance with treating carcinomas of the H&N (101) [2b]. There are no prospective trials regarding radiotherapy of H&N sarcomas. The evidence on the role of radiotherapy is derived from data base (102) [2c] and 2 retrospective studies (103, 104) [2b], all suggesting

that adjuvant post-operative radiotherapy is feasible and may lead to better control and superior survival than surgery alone.

Preoperative radiotherapy entails smaller volumes and lower doses compared with postoperative radiotherapy, and have therefore some advantages for H&N because of the close proximity to critical organs at risk (45, 102) [2c,1a].

In a retrospective study of 40 patients with H&N STS treated with pre-op RT (50 Gy) and subsequent (4 to 6 weeks later) resection, the actuarial 2-year local relapse-free rate was 80% and major wound complications occurred in 8 of 40 patients (20%) within 120 days of surgery (105) [3b]. These results suggested that pre-op radiotherapy in H&N STS is associated with lower rates of major wound complications compared to extremity cases and that it provides high rates of local control in this adverse group of patients (105) [3b].

27. Radiotherapy should be considered in high grade breast sarcoma patients operated with marginal margin and in patients with intralesional margins if re-excision cannot be performed (B)

Literature review and evidence description

Breast sarcomas can be of various histological subtypes. The most common are Phylloides breast tumours and angiosarcomas. Phylloides tumours are either benign, borderline or malignant while angiosarcomas can be spontaneous or radiation induced (following irradiation for carcinoma of the breast). Similar to localized STS in other sites, surgery is the main treatment for localized breast sarcomas (43, 45) [1a]. In the majority of breast sarcoma patients, total mastectomy including fasciectomy may be necessary to obtain adequate surgical margins(46). Dissection of the axillary lymph nodes is not routinely performed (43, 45, 46) [1a,1a,3b].

The evidence on the role of radiotherapy is derived exclusively from retrospective and database studies (106-115) [2b-2b,3b] since randomized trials are lacking. All studies suggest that, adjuvant postoperative radiotherapy, regardless of histological type, could reduce the risk of local recurrence in high-risk, patients (high grade and/or inadequate margin) without improving survival (106-115) [2b-2b,3b].

Based on these retrospective studies (106-115) [2b] and expert opinion expressed in various guidelines (43, 45, 46) [1a-1a,3b] and reviews (17) [2b], the strength of the evidence for the role of radiotherapy in breast sarcoma is evaluated as being strength B.

Patient values and preferences

Not relevant.

Rationale

Sarcomas can affect any site in the body and surgery is the main treatment of localized soft tissue sarcoma regardless of the site. The rationale of adding radiotherapy to the standard surgical intervention is not only to improve local control the disease but to preserve the function of the affected site/organ if possible and avoid mutilating surgical procedures.

Histology specific radiotherapy

- 28. Patients with myxoid liposarcoma (MLS), regardless of grade, should be considered for preoperative radiotherapy due to the unique radiosensitivity of this STS subtype (B)**
- 29. Patients with rhabdomyosarcoma should be treated according to the results of the most recent European rhabdomyosarcoma protocol (EpSSG, FAR-RMS) as detailed in appendix 3 (A)**

Literature and evidence review

Retrospective data highlight the unique radiosensitivity of MLS, where preoperative radiotherapy results in reliable tumour shrinkage (60% volume decrease(116)), and radiological distance from tumor to nerve-vessel-bundle and other critical structures can be increased (2 mm to 5 mm(117)). A prospective study confirmed that these benefits are sustained even after a dose-reduced preoperative fractionation of 2 Gy x 18, 5 fractions p. week, total dose 36 Gy(60), reducing acute and late side effects. Especially in patients where surgery is expected to be marginal, preoperative radiotherapy should be discussed in a MDT setting (B).

There are accumulated evidence from randomized studies that Rhabdomyosarcoma should have specific dosage and indications. Prospective randomized clinical trials lead by international organizations as the European paediatric soft tissue study group (EpSSG) and the German Cooperative Soft Tissue Sarcoma Studies (CWS) are defining the standard treatment in most European countries. EpSSG protocols have been the standard of care in Denmark for the last decades. Rhabdomyosarcoma protocols are valid for both children and adults. The current doses and indications are summarized in Table 1 and 2 and are derived from 10 publications (118-125) [1b] based on data from the prospective protocols. Detailed radiotherapy description of the most recent EpSSG protocol (FAR-RMS) is attached in appendix 3 and summarized in the tables below.

Table 1: Rhabdomyosarcoma indications and doses

Indication	Risk group	Embryonal dose & fx	Alveolar Dose & Fx
<i>initial complete resection, no microscopic or macroscopic residual tumour, no lymph node involvement</i>	I	No Rth	41.4 Gy; 23 fx.
<i>grossly resected tumour with microscopic residual disease or evidence of regional lymph node involvement</i>	II	41.4 Gy; 23 fx	41.4 Gy; 23 fx
<i>initial incomplete resection with gross residual disease. Followed by secondary complete resection</i>	III a	36 Gy; 20 fx (if PR)	41.4 Gy; 23 fx

		41.4 Gy; 23 fx (if SD)	
<i>initial incomplete resection with gross residual disease followed by incomplete secondary resection</i>	IIIb	50.4 Gy; 23 fx	50.4 Gy; 23 fx
<i>initial incomplete resection with gross residual disease followed by clinical CR. No second look operation</i>	IIIc	41.4 Gy; 23 fx	50.4 Gy; 23 fx
<i>initial incomplete resection with gross residual disease followed by PRn NC or PD, no second look operation</i>	IIId	50.4 Gy; 23 fx 0 boost 5.4 Gy; 3fx Except orbit & PR 45 Gy; 25fx	50.4 Gy; 23 fx + boost 5.4 Gy; 3fx

Table 2. Radiation dose for the lymph nodes

Situation	Embryonal/Alveolar RMS
<i>No Clinical or pathological involvement of regional nodes</i>	No Radiotherapy
<i>Clinically or pathologically positive lymph nodes; excised or in complete remission before radiotherapy</i>	41.4 Gy; 23 fractions
<i>Positive Lymph nodes, macroscopical residual disease before radiotherapy</i>	41.4 Gy; 23 fractions + 9Gy boost in 5 fractons

Based on the evidence derived from publications based on prospective trials (118-125) [1b], reviews (126) [1b] and best standard of care in international protocol (appendix 3), the strength of evidence for the role of radiotherapy in rhabdomyosarcoma is considered to be strength A.

Patient values and preferences

Not relevant.

Rationale

No prospective randomized data are available with regards to the value of preoperative radiotherapy in MLS. For STS as a whole preoperative radiotherapy is considered equally effective compared to postoperative radiotherapy. There is retrospective evidence for MLS being the only subtype where a downstaging can be

achieved by radiotherapy, as presented above. Therefore, preoperative radiotherapy should be considered for this subtype if surgically acceptable.

The current practice according to the most recent EpSSG guidelines is based on a risk stratification strategy that adjusts treatment intensity according to the risk of death from disease and takes into account patients age and the anatomical site of the disease.

Proton therapy

30. Children and young adult patients receiving high dose radiotherapy for soft tissue sarcomas in critical sites such as the head and neck, paraspinal region, pelvis and base of skull should be considered for Proton therapy (B)

Literature and evidence review

No randomized studies compare particle therapy with photons in sarcoma treatment. The superior dose distribution and improved conformity of protons combined with better sparing of normal tissue have been presented as an argument for implementing particle therapy without positive phase III studies (127) [2b] particularly in rare tumours as sarcomas and in children where the risk of late secondary cancer is of particular concern (128) [c]. The evidence for the value of proton therapy was therefore derived from retrospective studies displaying clinical benefits of particle therapy in primary and recurrent sarcomas in sites such as the head and neck, pelvis/abdomen and paraspinal regions (27, 129-139) [c,c,3b,2b,2b,2b,2b,2b,3b,3b,3b,,2b].

Based on evidence derived only from retrospective studies of small number of patients the strength of evidence for the role of proton therapy in treatment of soft tissue sarcoma is considered to be strength B.

4. References

1. Gerner RE, Moore GE, Pickren JW. Soft tissue sarcomas. *Annals of surgery*. 1975;181(6):803-8.
2. Lindberg RD, Martin RG, Romsdahl MM, Barkley HT, Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. *Cancer*. 1981;47(10):2391-7.
3. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. *Ann Surg*. 1982;196(3):305-15.
4. Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. *Ann Surg Oncol*. 2014;21(8):2484-9.
5. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. *J Clin Oncol*. 1998;16(1):197-203.
6. Harrison LB, Franzese F, Gaynor JJ, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. *Int J Radiat Oncol Biol Phys*. 1993;27(2):259-65.
7. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. *J Clin Oncol*. 1996;14(3):859-68.
8. Italiano A, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, et al. Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting. *Cancer*. 2014;120(21):3361-9.
9. Jebens NL, Trovik CS, Bauer HC, Rydholm A, Monge OR, Hall KS, et al. Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study. *Int J Radiat Oncol Biol Phys*. 2008;71(4):1196-203.
10. Fujiwara T, Tsuda Y, Le Nail LR, Evans S, Gregory J, Tillman R, et al. The role of radiotherapy in the treatment of superficial soft-tissue sarcomas. *Bone Joint J*. 2020;102-B(8):1088-94.
11. Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(Suppl 4):iv268-iv9.
12. Rydholm A, Gustafson P, Rooser B, Willen H, Berg NO. Subcutaneous sarcoma. A population-based study of 129 patients. *J Bone Joint Surg Br*. 1991;73(4):662-7.
13. Tsagozis P, Bauer HC, Styring E, Trovik CS, Zaikova O, Brosjo O. Prognostic factors and follow-up strategy for superficial soft-tissue sarcomas: Analysis of 622 surgically treated patients from the scandinavian sarcoma group register. *J Surg Oncol*. 2015;111(8):951-6.
14. Saxby NE, An Q, Miller BJ. Local Recurrence of Soft Tissue Sarcoma Revisited: Is there a Role for "Selective" Radiation? *Iowa Orthop J*. 2022;42(1):239-48.
15. Larrier NA, Czito BG, Kirsch DG. Radiation Therapy for Soft Tissue Sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy. *Surg Oncol Clin N Am*. 2016;25(4):841-60.
16. Pisters PW, O'Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. *J Clin Oncol*. 2007;25(8):1003-8.

17. Strander H, Turesson I, Cavallin-Stahl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. *Acta Oncol.* 2003;42(5-6):516-31.
18. Alektiar KM, Velasco J, Zelefsky MJ, Woodruff JM, Lewis JJ, Brennan MF. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. *Int J Radiat Oncol Biol Phys.* 2000;48(4):1051-8.
19. Tang YW, Lai CS. The significance of close but negative excision margin for treatment of soft-tissue sarcoma. *Ann Plast Surg.* 2012;69(6):633-6.
20. Choong PF, Petersen IA, Nascimento AG, Sim FH. Is radiotherapy important for low-grade soft tissue sarcoma of the extremity? *Clin Orthop Relat Res.* 2001(387):191-9.
21. Mollabashy A, Virkus WW, Zlotecki RA, Berrey BH, Scarborough MT. Radiation therapy for low-grade soft tissue sarcoma. *Clin Orthop Relat Res.* 2002(397):190-5.
22. Alektiar KM, Leung D, Zelefsky MJ, Brennan MF. Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity. *J Clin Oncol.* 2002;20(6):1643-50.
23. Pisters PW, Pollock RE, Lewis VO, Yasko AW, Cormier JN, Respondek PM, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. *Ann Surg.* 2007;246(4):675-81; discussion 81-2.
24. Schreiber D, Rineer J, Katsoulakis E, Sroufe RL, Lange CS, Nwokedi E, et al. Impact of postoperative radiation on survival for high-grade soft tissue sarcoma of the extremities after limb sparing radical resection. *Am J Clin Oncol.* 2012;35(1):13-7.
25. Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. *Int J Radiat Oncol Biol Phys.* 2005;63(3):852-9.
26. Allignet B, Waissi W, Geets X, Dufresne A, Brahmi M, Ray-Coquard I, et al. Long-term outcomes after definitive radiotherapy with modern techniques for unresectable soft tissue sarcoma. *Radiother Oncol.* 2022;173:55-61.
27. Weber DC, Rutz HP, Bolsi A, Pedroni E, Coray A, Jermann M, et al. Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer institute experience. *Int J Radiat Oncol Biol Phys.* 2007;69(3):865-71.
28. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. *Lancet.* 2002;359(9325):2235-41.
29. Davis AM, O'Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. *J Clin Oncol.* 2002;20(22):4472-7.
30. Davis AM, O'Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. *Radiother Oncol.* 2005;75(1):48-53.
31. Al-Absi E, Farrokhyar F, Sharma R, Whelan K, Corbett T, Patel M, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. *Ann Surg Oncol.* 2010;17(5):1367-74.
32. Sampath S, Schultheiss TE, Hitchcock YJ, Randall RL, Shrieve DC, Wong JY. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. *Int J Radiat Oncol Biol Phys.* 2011;81(2):498-505.
33. Kungwengwe G, Clancy R, Vass J, Slade R, Sandhar S, Dobbs TD, et al. Preoperative versus Post-operative Radiotherapy for Extremity Soft tissue Sarcoma: a Systematic Review and Meta-analysis of Long-term Survival. *J Plast Reconstr Aesthet Surg.* 2021;74(10):2443-57.

34. Salerno KE, Alektiar KM, Baldini EH, Bedi M, Bishop AJ, Bradfield L, et al. Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. *Pract Radiat Oncol*. 2021;11(5):339-51.
35. Zagars GK, Ballo MT. Sequencing radiotherapy for soft tissue sarcoma when re-resection is planned. *Int J Radiat Oncol Biol Phys*. 2003;56(1):21-7.
36. Dagan R, Indelicato DJ, McGee L, Morris CG, Kirwan JM, Knapik J, et al. The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity. *Cancer*. 2012;118(12):3199-207.
37. Alamanda VK, Song Y, Shinohara E, Schwartz HS, Holt GE. Postoperative radiation boost does not improve local recurrence rates in extremity soft tissue sarcomas. *J Med Imaging Radiat Oncol*. 2014;58(5):633-40.
38. Al Yami A, Griffin AM, Ferguson PC, Catton CN, Chung PW, Bell RS, et al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary? *Int J Radiat Oncol Biol Phys*. 2010;77(4):1191-7.
39. Ballo MT, Zagars GK, Cormier JN, Hunt KK, Feig BW, Patel SR, et al. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. *Int J Radiat Oncol Biol Phys*. 2004;58(5):1461-7.
40. Fourquet J, Sunyach MP, Vilotte F, Le Pechoux C, Ranchere-Vince D, Bonvalot S, et al. Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. *Radiother Oncol*. 2016;120(1):156-62.
41. Merimsky O, Soyfer V, Kovner F, Bickels J, Issakov J, Flusser G, et al. Limb sparing approach: adjuvant radiation therapy in adults with intermediate or high-grade limb soft tissue sarcoma. *Radiother Oncol*. 2005;77(3):295-300.
42. Schwartz DL, Einck J, Hunt K, Bruckner J, Conrad E, Koh WJ, et al. The effect of delayed postoperative irradiation on local control of soft tissue sarcomas of the extremity and torso. *Int J Radiat Oncol Biol Phys*. 2002;52(5):1352-9.
43. (NCCN) Nccn. Clinical practice guidelines in oncology.
44. Australia CC. Australian clinical practice guidelines for the management of adult onset sarcoma 2020 [Available from: https://wiki.cancer.org.au/australia/Clinical_question:What_is_the_evidence_for_radiotherapy_in_limb_and_extremity_soft_tissue_sarcoma_in_terms_of_local_recurrence_survival_and_limb_salvage%3F.
45. Group SS. Recommendations for Radiotherapy in Bone- and Soft Tissue Sarcoma. 2015.
46. Pollack A, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters PW. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. *Int J Radiat Oncol Biol Phys*. 1998;42(3):563-72.
47. Jebesen NL, Engellau J, Engstrom K, Bauer HC, Monge OR, Muren LP, et al. Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. *Int J Radiat Oncol Biol Phys*. 2013;86(5):949-55.
48. Levy A, Bonvalot S, Bellefqih S, Terrier P, Le Cesne A, Le Pechoux C. Is dose de-escalation possible in sarcoma patients treated with enlarged limb sparing resection? *Radiother Oncol*. 2018;126(3):493-8.
49. Zagars GK, Ballo MT. Significance of dose in postoperative radiotherapy for soft tissue sarcoma. *Int J Radiat Oncol Biol Phys*. 2003;56(2):473-81.
50. Dinges S, Budach V, Budach W, Feldmann HJ, Stuschke M, Sack H. Local recurrences of soft tissue sarcomas in adults: a retrospective analysis of prognostic factors in 102 cases after surgery and radiation therapy. *Eur J Cancer*. 1994;30A(11):1636-42.

51. Wolfson AH, Benedetto PW, Mnaymneh W, Moffat FL, Robinson DS, Boyer C, et al. Does a radiation dose-response relation exist concerning survival of patients who have soft-tissue sarcomas of the extremities? Radiation dose-response relation for soft-tissue sarcomas. *Am J Clin Oncol*. 1998;21(3):270-4.
52. Delaney TF, Kepka L, Goldberg SI, Hornicek FJ, Gebhardt MC, Yoon SS, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. *Int J Radiat Oncol Biol Phys*. 2007;67(5):1460-9.
53. Kubicek GJ, LaCouture T, Kaden M, Kim TW, Lerman N, Khrizman P, et al. Preoperative Radiosurgery for Soft Tissue Sarcoma. *Am J Clin Oncol*. 2018;41(1):86-9.
54. Le Pechoux C, Le Deley MC, Delaloge S, Lartigau E, Levy-Piedbois C, Bonvalot S, et al. Postoperative radiotherapy in the management of adult soft tissue sarcoma of the extremities: results with two different total dose, fractionation, and overall treatment time schedules. *Int J Radiat Oncol Biol Phys*. 1999;44(4):879-86.
55. Raval RR, Frassica D, Thornton K, Meyer C, Ettinger DS, Frassica F, et al. Evaluating the Role of Interdigitated Neoadjuvant Chemotherapy and Radiation in the Management of High-Grade Soft-Tissue Sarcoma: The Johns Hopkins Experience. *Am J Clin Oncol*. 2017;40(2):214-7.
56. Soyfer V, Corn BW, Kollender Y, Issakov J, Dadia S, Flusser G, et al. Hypofractionated adjuvant radiation therapy of soft-tissue sarcoma achieves excellent results in elderly patients. *Br J Radiol*. 2013;86(1028):20130258.
57. Potkrajic V, Traub F, Hermes B, Scharpf M, Kolbensschlag J, Zips D, et al. Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population. *Radiol Oncol*. 2021;55(4):459-66.
58. Konieczkowski DJ, Goldberg SI, Raskin KA, Lozano-Calderon S, Mullen JT, Chen YL, et al. Low-dose preoperative radiation, resection, and reduced-field postoperative radiation for soft tissue sarcomas. *J Surg Oncol*. 2021;124(3):400-10.
59. Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, et al. A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. *Clin Cancer Res*. 2020;26(8):1829-36.
60. Lansu J, Braam PM, van Werkhoven E, Scholten AN, Schrage Y, van Houdt WJ, et al. A moderate dose of preoperative radiotherapy may improve resectability in myxoid liposarcoma. *Eur J Surg Oncol*. 2021;47(10):2633-9.
61. Mundt AJ, Awan A, Sibley GS, Simon M, Rubin SJ, Samuels B, et al. Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results. *Int J Radiat Oncol Biol Phys*. 1995;32(4):977-85.
62. Kim B, Chen YL, Kirsch DG, Goldberg SI, Kobayashi W, Kung JH, et al. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. *Int J Radiat Oncol Biol Phys*. 2010;77(3):843-50.
63. Dickie CI, Griffin AM, Parent AL, Chung PW, Catton CN, Svensson J, et al. The relationship between local recurrence and radiotherapy treatment volume for soft tissue sarcomas treated with external beam radiotherapy and function preservation surgery. *Int J Radiat Oncol Biol Phys*. 2012;82(4):1528-34.
64. Peeken JC, Knie C, Kessel KA, Habermehl D, Kampfer S, Dapper H, et al. Neoadjuvant image-guided helical intensity modulated radiotherapy of extremity sarcomas - a single center experience. *Radiat Oncol*. 2019;14(1):2.
65. Choi N, Kim JY, Yu T, Kang HC, Kim HS, Kim HJ, et al. Does fluid collection impact radiotherapy outcomes after wide excision of lower extremity soft tissue sarcoma? *Jpn J Clin Oncol*. 2018;48(2):153-9.

66. Baldini EH, Wang D, Haas RL, Catton CN, Indelicato DJ, Kirsch DG, et al. Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. *Int J Radiat Oncol Biol Phys*. 2015;92(3):602-12.
67. Haas RL, Miah AB, LePechoux C, DeLaney TF, Baldini EH, Alektiar K, et al. Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. *Radiother Oncol*. 2016;119(1):14-21.
68. Tiong SS, Dickie C, Haas RL, O'Sullivan B. The role of radiotherapy in the management of localized soft tissue sarcomas. *Cancer Biol Med*. 2016;13(3):373-83.
69. Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. *J Clin Oncol*. 2008;26(20):3440-4.
70. Alektiar KM, Hong L, Brennan MF, Della-Biancia C, Singer S. Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. *Int J Radiat Oncol Biol Phys*. 2007;68(2):458-64.
71. Di Brina L, Fogliata A, Navarria P, D'Agostino G, Franzese C, Franceschini D, et al. Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. *Br J Radiol*. 2019;92(1102):20190252.
72. Folkert MR, Singer S, Brennan MF, Kuk D, Qin LX, Kobayashi WK, et al. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. *J Clin Oncol*. 2014;32(29):3236-41.
73. Lin C, Donaldson SS, Meza JL, Anderson JR, Lyden ER, Brown CK, et al. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group. *Int J Radiat Oncol Biol Phys*. 2012;82(5):1764-70.
74. O'Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. *Cancer*. 2013;119(10):1878-84.
75. Smith KB, Indelicato DJ, Knapik JA, Morris C, Kirwan J, Zlotecki RA, et al. Definitive radiotherapy for unresectable pediatric and young adult nonrhabdomyosarcoma soft tissue sarcoma. *Pediatr Blood Cancer*. 2011;57(2):247-51.
76. Stewart AJ, Lee YK, Saran FH. Comparison of conventional radiotherapy and intensity-modulated radiotherapy for post-operative radiotherapy for primary extremity soft tissue sarcoma. *Radiother Oncol*. 2009;93(1):125-30.
77. Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, et al. Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial. *J Clin Oncol*. 2015;33(20):2231-8.
78. Wang J, Song Y, Liu X, Jin J, Wang W, Yu Z, et al. Comparison of outcome and toxicity of postoperative intensity-modulated radiation therapy with two-dimensional radiotherapy in patients with soft tissue sarcoma of extremities and trunk. *Cancer Med*. 2019;8(3):902-9.
79. Casey DL, Berry SL, Crago A, Fabbri N, Singer S, Alektiar KM. Femoral Fracture in Primary Soft Tissue Sarcoma Treated with Intensity-Modulated Radiation Therapy with and Without Dose Constraints. *Ann Surg Oncol*. 2021;28(5):2700-4.
80. Folkert MR, Casey DL, Berry SL, Crago A, Fabbri N, Singer S, et al. Femoral Fracture in Primary Soft-Tissue Sarcoma of the Thigh and Groin Treated with Intensity-Modulated Radiation Therapy: Observed versus Expected Risk. *Ann Surg Oncol*. 2019;26(5):1326-31.

81. Dickie CI, Parent AL, Griffin AM, Fung S, Chung PW, Catton CN, et al. Bone fractures following external beam radiotherapy and limb-preservation surgery for lower extremity soft tissue sarcoma: relationship to irradiated bone length, volume, tumor location and dose. *Int J Radiat Oncol Biol Phys.* 2009;75(4):1119-24.
82. Bonvalot S, Gronchi A, Le Pechoux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2020;21(10):1366-77.
83. Catton CN, O'Sullivan B, Kotwall C, Cummings B, Hao Y, Fornasier V. Outcome and prognosis in retroperitoneal soft tissue sarcoma. *Int J Radiat Oncol Biol Phys.* 1994;29(5):1005-10.
84. Cosper PF, Olsen J, DeWees T, Van Tine BA, Hawkins W, Michalski J, et al. Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience. *Radiat Oncol.* 2017;12(1):198.
85. Pawlik TM, Pisters PW, Mikula L, Feig BW, Hunt KK, Cormier JN, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. *Ann Surg Oncol.* 2006;13(4):508-17.
86. Zlotecki RA, Katz TS, Morris CG, Lind DS, Hochwald SN. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience. *Am J Clin Oncol.* 2005;28(3):310-6.
87. Bonvalot S, Gronchi A, Le Pechoux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2020;21(10):1366-77.
88. Green WR, Chokshi R, Jabbour SK, DeLaney TF, Mahmoud O. Utilization pattern and survival outcomes of adjuvant therapies in high-grade nonretroperitoneal abdominal soft tissue sarcoma: A population-based study. *Asia Pac J Clin Oncol.* 2018;14(1):101-13.
89. Reed NS, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). *Eur J Cancer.* 2008;44(6):808-18.
90. Ferrer F, Sabater S, Farrus B, Guedea F, Roviro A, Anglada L, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita. *Int J Radiat Oncol Biol Phys.* 1999;44(1):47-52.
91. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. *Eur J Surg Oncol.* 2001;27(3):282-5.
92. Livi L, Paiar F, Shah N, Blake P, Villanucci A, Amunni G, et al. Uterine sarcoma: twenty-seven years of experience. *Int J Radiat Oncol Biol Phys.* 2003;57(5):1366-73.
93. Magnuson WJ, Petereit DG, Anderson BM, Geye HM, Bradley KA. Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma. *Anticancer Res.* 2015;35(1):365-70.
94. Malouf GG, Lhomme C, Duvillard P, Morice P, Haie-Meder C, Pautier P. Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. *Int J Gynaecol Obstet.* 2013;122(1):57-61.
95. Philip CA, Pautier P, Duffaud F, Ray-Coquard I. High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches. *Curr Oncol Rep.* 2014;16(10):405.
96. Sampath S, Gaffney DK. Role of radiotherapy treatment of uterine sarcoma. *Best Pract Res Clin Obstet Gynaecol.* 2011;25(6):761-72.

97. Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. *Int J Radiat Oncol Biol Phys.* 2010;76(3):728-34.
98. Terek MC, Akman L, Hursitoglu BS, Sanli UA, Ozsaran Z, Tekindal MA, et al. The retrospective analysis of patients with uterine sarcomas: A single-center experience. *J Cancer Res Ther.* 2016;12(1):309-13.
99. Weitmann HD, Knocke TH, Kucera H, Potter R. Radiation therapy in the treatment of endometrial stromal sarcoma. *Int J Radiat Oncol Biol Phys.* 2001;49(3):739-48.
100. Yu T, Kim HJ, Wu HG, Ha SW, Song YS, Park NH, et al. Outcome analysis in patients with uterine sarcoma. *Radiat Oncol J.* 2015;33(1):29-35.
101. Linthout N, Verellen D, Tournel K, Storme G. Six dimensional analysis with daily stereoscopic x-ray imaging of intrafraction patient motion in head and neck treatments using five points fixation masks. *Med Phys.* 2006;33(2):504-13.
102. Mahmoud O, Beck R, Kalyoussef E, Chan Park R, Baredes S, Kim S, et al. Adjuvant therapies utilization pattern and survival outcomes in high-grade head and neck soft tissue sarcoma; a population based study. *Oral Oncol.* 2017;66:28-37.
103. Glosli H, Bisogno G, Kelsey A, Chisholm JC, Gaze M, Kolb F, et al. Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study. *Eur J Cancer.* 2021;151:84-93.
104. Minard-Colin V, Kolb F, Saint-Rose C, Fayard F, Janot F, Rey A, et al. Impact of extensive surgery in multidisciplinary approach of pterygopalatine/infratemporal fossa soft tissue sarcoma. *Pediatr Blood Cancer.* 2013;60(6):928-34.
105. O'Sullivan B, Gullane P, Irish J, Neligan P, Gentili F, Mahoney J, et al. Preoperative radiotherapy for adult head and neck soft tissue sarcoma: assessment of wound complication rates and cancer outcome in a prospective series. *World J Surg.* 2003;27(7):875-83.
106. Barrow BJ, Janjan NA, Gutman H, Benjamin RS, Allen P, Romsdahl MM, et al. Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. *Radiother Oncol.* 1999;52(2):173-8.
107. Barth RJ, Jr. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. *Breast Cancer Res Treat.* 1999;57(3):291-5.
108. Barth RJ, Jr., Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. *Ann Surg Oncol.* 2009;16(8):2288-94.
109. Belkacemi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magne N, Malard Y, et al. Phyllodes tumor of the breast. *Int J Radiat Oncol Biol Phys.* 2008;70(2):492-500.
110. Ghareeb ER, Bhargava R, Vargo JA, Florea AV, Beriwal S. Primary and Radiation-induced Breast Angiosarcoma: Clinicopathologic Predictors of Outcomes and the Impact of Adjuvant Radiation Therapy. *Am J Clin Oncol.* 2016;39(5):463-7.
111. Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998-2009. *Ann Surg Oncol.* 2014;21(4):1222-30.
112. Jang JH, Choi MY, Lee SK, Kim S, Kim J, Lee J, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. *Ann Surg Oncol.* 2012;19(8):2612-7.
113. Kim YJ, Kim K. Radiation therapy for malignant phyllodes tumor of the breast: An analysis of SEER data. *Breast.* 2017;32:26-32.
114. Luini A, Gatti G, Diaz J, Botteri E, Oliveira E, Cecilio Sahium de Almeida R, et al. Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. *Breast Cancer Res Treat.* 2007;105(1):81-5.

115. McGowan TS, Cummings BJ, O'Sullivan B, Catton CN, Miller N, Panzarella T. An analysis of 78 breast sarcoma patients without distant metastases at presentation. *Int J Radiat Oncol Biol Phys.* 2000;46(2):383-90.
116. Allignet B, Meurgey A, Bouhamama A, Karanian M, Meeus P, Vaz G, et al. Impact of histological subtype on radiological and pathological response after neoadjuvant radiotherapy in soft tissue sarcoma. *Eur J Surg Oncol.* 2021;47(12):2995-3003.
117. Kaiser D, Schelm M, Gerber C, Brown ML, Müller DA. The effect of preoperative radiotherapy on surgical resectability, tumor volume and the necrosis rate of soft tissue sarcomas: A retrospective single-center analysis. *Surg Oncol.* 2021;39:101668.
118. Arndt CA, Donaldson SS, Anderson JR, Andrassy RJ, Laurie F, Link MP, et al. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? *Cancer.* 2001;91(12):2454-68.
119. Donaldson SS, Meza J, Breneman JC, Crist WM, Laurie F, Qualman SJ, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. *Int J Radiat Oncol Biol Phys.* 2001;51(3):718-28.
120. Koscielniak E, Schmidt B, Knietig R. Effectivity of a 32 Gy radiation dose in children with RMS: Report of the German Cooperative Soft Tissue Sarcoma Studies (CWS). *Med Pediatr Oncol.* 2001;37(186).
121. Martelli H, Oberlin O, Rey A, Godzinski J, Spicer RD, Bouvet N, et al. Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology. *J Clin Oncol.* 1999;17(7):2117-22.
122. Oberlin O, Rey A, Anderson J, Carli M, Raney RB, Treuner J, et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop. *J Clin Oncol.* 2001;19(1):197-204.
123. Regine WF, Fontanesi J, Kumar P, Ayers D, Bowman LC, Pappo AS, et al. Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients. *Int J Radiat Oncol Biol Phys.* 1995;31(3):485-91.
124. Schuck A, Mattke AC, Schmidt B, Kunz DS, Harms D, Knietig R, et al. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? *J Clin Oncol.* 2004;22(1):143-9.
125. Wolden SL, Anderson JR, Crist WM, Breneman JC, Wharam MD, Jr., Wiener ES, et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. *J Clin Oncol.* 1999;17(11):3468-75.
126. Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. *Paediatr Drugs.* 2002;4(1):21-8.
127. Suit H, Kooy H, Trofimov A, Farr J, Munzenrider J, DeLaney T, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. *Radiother Oncol.* 2008;86(2):148-53.
128. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. *Int J Radiat Oncol Biol Phys.* 2002;54(3):824-9.
129. Childs SK, Kozak KR, Friedmann AM, Yeap BY, Adams J, MacDonald SM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. *Int J Radiat Oncol Biol Phys.* 2012;82(2):635-42.
130. Cotter SE, Herrup DA, Friedmann A, Macdonald SM, Pieretti RV, Robinson G, et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. *Int J Radiat Oncol Biol Phys.* 2011;81(5):1367-73.

131. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. *Int J Radiat Oncol Biol Phys*. 2009;74(3):732-9.
132. Greiner R, Munkel G, Kann R, Blattmann H, Coray A, Thum P, et al. Pion irradiation at Paul Scherrer Institute. Results of dynamic treatment of unresectable soft tissue sarcoma. *Strahlenther Onkol*. 1990;166(1):30-3.
133. Guttman DM, Frick MA, Carmona R, Deville C, Jr., Levin WP, Berman AT, et al. A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma. *Radiother Oncol*. 2017;124(2):271-6.
134. Hug EB, Adams J, Fitzek M, De Vries A, Munzenrider JE. Fractionated, three-dimensional, planning-assisted proton-radiation therapy for orbital rhabdomyosarcoma: a novel technique. *Int J Radiat Oncol Biol Phys*. 2000;47(4):979-84.
135. Ladra MM, Edgington SK, Mahajan A, Grosshans D, Szymonifka J, Khan F, et al. A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. *Radiother Oncol*. 2014;113(1):77-83.
136. Ladra MM, Szymonifka JD, Mahajan A, Friedmann AM, Yong Yeap B, Goebel CP, et al. Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. *J Clin Oncol*. 2014;32(33):3762-70.
137. Nowakowski VA, Castro JR, Petti PL, Collier JM, Daftari I, Ahn D, et al. Charged particle radiotherapy of paraspinal tumors. *Int J Radiat Oncol Biol Phys*. 1992;22(2):295-303.
138. Timmermann B, Schuck A, Niggli F, Weiss M, Lomax AJ, Pedroni E, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute. *Int J Radiat Oncol Biol Phys*. 2007;67(2):497-504.
139. Weber DC, Trofimov AV, Delaney TF, Bortfeld T. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. *Int J Radiat Oncol Biol Phys*. 2004;58(5):1596-606.

5. Method

Literature search

The critical appraisal of the selected evidence was done by the author of the guidelines. The data on the selected radiotherapy parameter for example; dose or fractionation or technique were extracted from the article and measured against the selected outcome. The quality of the evidence depended on the study design and the number of patients as well as the ability of the study to account for possible confounders and modifiers. The strength of the recommendations was graded according to the strongest evidence (see evidens table, appendix 5)

Literature review

Evidence was looked for in Medline database using “Sarcoma” and “Radiotherapy” as a MESH terms. Details of the search terms are in the appendix (1). The search was restricted to English language human studies in adults. The following studies were excluded:

- Case reports
- Studies with less than 50 patients unless they are unique or providing the only evidence
- Studies with only paediatric population
- Studies describing brachytherapy or intraoperative radiotherapy

We didn't set a time frame but we ended up excluding most of the old studies dating before 1990 because they used old techniques and usually included few very limited number of patients. The search terms results included reviews and meta-analysis, so we didn't make specific search for reviews.

A second source of evidence was found in various international guidelines. Guidelines focusing on aspects other than radiotherapy, for example chemotherapy or palliative treatment were excluded.

A third source of evidence was sought in the radiotherapy guidelines in some previous and current international protocols such as the EpSSG rhabdomyosarcoma and non rhabdomyosarcoma protocols as well as or the EORTC STRASS protocol as well as in the Scandinavian sarcoma group radiotherapy guidelines they are describing the best standard radiotherapy practice. Some essential references in these protocols were retrieved and used (see flow chart, appendix 4).

Literature search for version 1.3

The original search was applied. The time frame was from January 1st 2019 to October 4th 2024. The following studies were excluded:

- Case reports and studies reporting on 10 patients or less
- Studies with less than 50 patients unless they are unique or providing the only evidence
- Studies with only paediatric population or mixed paediatric and adult population and no differentiated outcomes.
- Studies describing brachytherapy or intraoperative radiotherapy
- Studies with no relevant outcomes

International guidelines including updated versions of previously cited international guidelines were included for reference as well.

PRISMA flowchart for the update of the literature search is presented in the appendix (Appendix 4).

Formulation of the recommendations

The recommendation was formulated by the author of the guidelines in the first draft. The formulation will be revised by members of the DSG from various specialties to reach an expert consensus formulation.

Stakeholder involvement

There was no attempt at involving patients in the current guidelines as it was not considered possible.

Hearing

There was a continuous dialogue with SundK secretariat (former RKKP) during preparation of the guidelines. Feedback from secretariat was included and the guideline was modified accordingly. Members from DSG representing both oncologists and orthopaedic surgeons in the 2 national sarcoma centres received and commented the first draft of the guidelines and their comments were incorporated in the final version.

Approval

Content approval:

The guideline is professionally approved by DSG.

Administrative approval:

The guideline is administratively approved by Center for Clinical Practice Guidelines | Cancer

Recommendations that entail significant additional costs

No additional cost is estimated.

Need for further research

There is a need for further research to elucidate:

1. The value of preoperative radiotherapy, the value of dose escalation using protons, dose constraints in limb irradiation
2. The above-mentioned areas are still in need of further research at the date of version 1.3. Further areas where there is a need for further research: Preoperative radiotherapy combined with neoadjuvant systemic treatment; re-irradiation; palliative radiotherapy for patients with metastatic sarcoma; radiotherapy in patients with oligometastatic disease; practical guidelines including positioning and delivery of radiotherapy for sarcoma patients.

Authors and conflicts of interest

- Akmal Safwat, Consultant Clinical Oncology and Associate Prof. Aarhus University Hospital, the Department of Oncology and the Danish Centre for Particle Therapy (DCPT). No conflict of interest.
- Bodil Engelmann, Staff specialist in Clinical Oncology, Department of Oncology, Herlev Hospital, Chairman of the Danish Sarcoma Group Radiotherapy Subcommittee. Conflict of interest: Received in 2024 a consulting fee from Boeringer Ingelheim for a health-economy analysis of the cost related to treatment of patients with liposarcomas in Denmark.

The Chairman of the Danish Sarcoma Group has reviewed these conflicts of interest and did not find any concerns with regards to the conflict of interests of the authors.

For detailed cooperative relationships, please refer to the declaration via the Danish Medicines Agency's website: [List of proprietary pharmacists, doctors, nurses, dentists, proprietary pharmacists and prescribing pharmacists who have a relationship with a company](#)

Plan for revision

The guideline will be updated under the auspices of DSG in 2027.

Version of guideline template

The guideline has been developed in the 3.0 version of the template.

6. Monitoring

Standards and indicators

The revision of the guideline will be presented to the remaining members of the DSG during the next meeting in January. The yearly RKKP report should include enough information to monitor adherence to the guidelines, new indicators and audit mechanisms can be added later if needed.

7. Appendices

Appendix 1 – Search protocol

“Sarcoma/radiotherapy”[Majr] AND “soft tissue sarcoma”[All Fields] AND (“humans”[MeSH Terms] AND English[lang] AND “adult”[MeSH Terms])
(antal hits = 250)

Appendix 2 – Links to international radiotherapy soft tissue sarcoma guidelines

- Australian clinical practice guidelines for the management of adult onset sarcoma. Available at: [https://wiki.cancer.org.au/australia/Clinical_question:What is the evidence for radiotherapy in limb and extremity soft tissue sarcoma in terms of local recurrence, survival and limb salvage%3F](https://wiki.cancer.org.au/australia/Clinical_question:What_is_the_evidence_for_radiotherapy_in_limb_and_extremity_soft_tissue_sarcoma_in_terms_of_local_recurrence_survival_and_limb_salvage%3F). Accessed 2013.
 - Scandinavian Sarcoma Group recommendation for radiotherapy of bone and soft tissue sarcoma: Available at:
 - <http://www.ssg-org.net/wp-content/uploads/2011/05/SSG-RT-Guidelines-December-2015.pdf>. Accessed 2015.
 - National comprehensive cancer network (NCCN) Clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf. Accessed 2018.
-

Version 1.3:

- Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: An ASTRO Clinical Practice Guideline
Kilian E. Salerno, Kaled M. Alektiar, Elizabeth H. Baldini, et al. Available at: <https://www.astro.org/patient-care-and-research/clinical-practice-statements/clinical-practice-guidelines/soft-tissue-sarcoma-gl>. Accessed dec 2024.
 - Conformal radiotherapy in management of soft tissue sarcoma in adults Radiothérapie conformationnelle dans la prise en charge des sarcomes des tissus mous de l'adulte, C. Le Péchoux, C. Llacer, P. Sargos et al. [Cancer/Radiothérapie, Vol 26, Issues 1–2](#), February–April 2022, Pages 377-387
-

Appendix 3 – Radiotherapy guidelines in EpSSG soft tissue sarcoma protocols

1- Rhabdomyosarcoma based on FAR-RMS protocol

Timing of local therapy

The decision to proceed to local therapy (surgery and/or radiotherapy) should be made after 3 cycles of induction chemotherapy (or after 6 cycles for patients with metastatic disease). Where a patient is deemed suitable for radiotherapy, radiotherapy randomisations should be considered, as patients may be eligible to enter multiple radiotherapy questions.

The Union for International Cancer Control (UICC), which describes the absence or presence of residual tumour after treatment by the symbol R, will be used to express the quality of surgery.

The R categories are:

- R0 = no residual tumour
- R1 = microscopic residual tumour
- R2 = macroscopic residual tumour

Where a patient is not eligible for a radiotherapy 43mprove4343d43on patients should be treated in accordance with the FaR-RMS Quartet RTQA Radiotherapy and Imaging Guidelines.

Preoperative, or definitive, radiotherapy for 43mprove4343 disease should be delivered after 4th cycle of chemotherapy (week 13), or after 7th cycle of chemotherapy for metastatic disease (week 22), with surgery then 4- 6 weeks after completion of radiotherapy.

Postoperative radiotherapy should commence with the 2nd cycle of postoperative chemotherapy, surgery having taken place at after 4th cycle of chemotherapy (week 13), or after 7th cycle of chemotherapy for metastatic disease (week 22).

Indications for radiotherapy

Radiotherapy to the site of the primary tumour is indicated for the majority patients, particularly those in the HR and VHR Groups; and the majority of Standard Risk Patients (Group C only).

Key exceptions which do not require radiotherapy are:

- Localised fusion negative rhabdomyosarcoma with initial R0 resection (IRS Group I) i.e. subgroups A and B
- Localised fusion negative rhabdomyosarcoma of the vagina achieving complete remission with induction chemotherapy

- A highly selected group of patients with IRS Group II/ III Standard Risk fusion negative RMS, arising at a favourable site, where secondary surgery achieves an R0 resection (e.g. paratesticular, uterus) i.e. subgroup C

Note patients in subgroup C with IRS Group II/ III Standard Risk fusion negative RMS, at other favourable sites are likely to require radiotherapy (and may be eligible for the radiotherapy 44mprove4444d44on) e.g. bladder/ prostate; head and neck RMS, orbit, biliary.

Nodal disease: Radiotherapy should be delivered to all regional nodal sites involved at the time of presentation, irrespective of any additional surgical resection.

Metastatic disease: Radiotherapy should be delivered to all sites of metastatic disease that can feasibly be treated, unless patient being treated in the metastatic radiotherapy 44mprove4444d44on.

Children <2 years of age will not be eligible for the radiotherapy randomisations. Adherence to the FaR RMS Quartet RTQA guidelines is encouraged; however, the decision to proceed with radiotherapy is at the discretion of the treating clinicians, considering tumour histology, tumour site, response to chemotherapy, and the potential late morbidity of local therapy.

Standard radiotherapy details

Where adjuvant radiotherapy to the primary tumour is indicated in addition to surgical resection, radiotherapy can be given either pre or post operatively.

For patients with a higher local failure risk (HLFR) standard dose radiotherapy is 41.4Gy with the additional 9Gy for dose escalated patients delivered to the extent of tumour remaining after induction chemotherapy.

Patients with standard Local Failure Risk (SLFR) will receive 41.4Gy adjuvant radiotherapy in addition to surgery achieving an R0 or R1 resection.

Patients with unresectable disease with a complete response following induction therapy should be treated with standard dose radiotherapy for microscopic disease and receive 41.4Gy.

For patients whose tumour is not suitable for surgical resection, with an incomplete response following induction therapy, and where there is a HLFR, standard dose radiotherapy is 50.4Gy delivered to the extent of tumour at diagnosis, with the additional 9Gy (standard) delivered to the extent of tumour remaining after induction chemotherapy.

SLFR patients, and patients where surgery has only achieved an R2 resection will be treated with standard dose radiotherapy for macroscopic disease receiving 50.4Gy as described above. This is the standard dose for all patients receiving definitive radiotherapy treatment.

Radiotherapy facilities and planning

Patients can receive radiotherapy treatment to the primary tumour using photon-based techniques (including IMRT), or proton therapy/particle therapy. Patients can receive radiotherapy to metastatic sites using these same techniques, although other photon radiotherapy techniques including SBRT or SRT may also be used. A Simultaneous Integrated Boost (SIB) technique may be considered, and acceptable schedules are detailed in the FaR-RMS Quartet RTQA Guidelines.

Patient position and data acquisition

Appropriate immobilization or motion mitigation strategies, depending on localization, are expected. All patients should be planned on a planning CT of appropriate slice thickness (typically 1-3mm) with the aid of all diagnostic and response assessment imaging available.

Definition of Radiotherapy Target Volumes & Margins**GTV**

For radiotherapy treatment of the Primary Tumour Volume the Gross Tumour Volume (GTV) at presentation (GTVp_pre) will be delineated (or reconstructed) for all cases; this referring to the extent of disease at diagnosis, taking into account changes in anatomy and organ displacement resulting from chemotherapy related tumour shrinkage, or surgical resection.

For cases receiving definitive primary radiotherapy (including both arms of RT1c), and those receiving adjuvant radiotherapy 45 Gy to the dose escalation arm in RT1b, an additional GTV will be defined based on the extent of the residual primary tumour on imaging obtained post induction chemotherapy (GTVp_post), taking into account changes in anatomy, and organ displacement, resulting from chemotherapy related tumour shrinkage, or surgical resection.

The nodal GTV (GTVn) should be delineated based on the gross extent of nodal involvement at diagnosis taking into account changes in anatomy and organ displacement resulting from chemotherapy related tumour shrinkage, or surgical resection. For exceptional cases with pathologically enlarged bulky macroscopic residual nodal disease post induction chemotherapy an additional boost should be delivered with this residual disease delineated as GTVn_post

CTV

Clinical Target Volumes (CTV) for the Primary tumour (CTVp) will be generated using the following margins:

- GTVp_pre to CTVp_pre: 1 cm
- For extremity primary tumour sites, superior and inferior CTV margins of 2 cm are required, with 1cm expansion circumferentially.
- Skin, scar, drain or biopsy sites should not be included in the CTVp, except in cases of involvement with gross tumour.
- GTVp_post to CTVp_post: 0.5 cm

- For tumours arising adjacent to body cavities (e.g. thorax, abdomen, pelvis) that extend or 'push' into the cavity but do not infiltrate adjacent organs or tissues, then the GTVp should only be expanded, by 1cm (GTVp_pre) or 0.5cm (GTVp_post), in the direction of potential infiltration, and there should be no extension of the CTVp into the adjacent, uninvolved body cavity.
- GTVn to CTVn: 3cm superiorly and inferiorly (or in direction of nodal drainage), and circumferentially to include adjacent lymph nodes in the anatomically constrained lymph node site. Wherever possible, displaced normal tissue should be excluded from the CTVn. In cases of uncertainty, or where particular concern, about exact extent of nodal involvement at diagnosis then an involved field concept should be used.
- For bulky residual involved lymph nodes, GTVn_post to CTVn_post: 0.5 cm

ITV

For primary tumour sites where respiratory-related motion needs to be considered (e.g. thorax, upper abdomen) the use of 4DCT and an Internal Target Volume (ITV) approach is allowed, based on local practice. This will be denoted as ITVp.

PTV

Expansion from the CTVs or ITVs to PTVs is to be undertaken as per local standard of care, based on the specific radiotherapy technique, image guidance strategy and set up errors, and is usually in the range of 3 to 10 mm.

Radiotherapy treatment to the primary tumour

Definition Dose Prescription and Dose Fractionation for primary tumour

- **Resectable pre or post-op radiotherapy HLFR Standard dose** = 41.4Gy in 23 fractions over 4.5 weeks(or equivalent) to PTVp_pre
- **Resectable pre or post-op radiotherapy SLFR Standard dose** = 41.4Gy in 23 fractions over 4.5 weeks(or equivalent) to PTVp_pre
- **Unresectable complete response (to induction chemotherapy) Standard dose** = 41.4Gy in 23 fractions over 4.5 weeks (or equivalent) to PTVp_pre
- **Unresectable incomplete response (to induction chemotherapy) HLFR Standard dose** = 50.4Gy in 28 fractions over 5.5 weeks (or equivalent) total. Phase 1: 41.4Gy in 23 fractions over 4.5 weeks(or equivalent) to PTVp_pre, Phase 2: 9Gy in 5 fractions (or equivalent) to PTVp_post
- **Unresectable incomplete response (to induction chemotherapy) SLFR Standard dose** = 50.4Gy in 28 fractions over 5.5 weeks (or equivalent) total. Phase 1: 41.4Gy in 23 fractions over 4.5 weeks (or equivalent) to PTVp_pre, Phase 2: 9Gy in 5 fractions (or equivalent) to PTVp_post

Dose Prescription and Dose Fractionation for involved lymph nodes

- 41.4Gy in 23 fractions over 4.5 weeks (or equivalent) to PTVn.

- For bulky residual involved lymph nodes only, Phase 2: 9Gy in 5 fractions (or equivalent) to PTVn_post

Radiotherapy treatment to metastatic sites

Patients with favourable metastatic disease, defined Modified Oberlin Prognostic Score of ≤ 1 (see section 16.2.2.5), will receive radical treatment of all metastases where feasible (standard of care).

Patients with unfavourable metastatic disease, defined as Modified Oberlin Prognostic Score of ≥ 2 , will be judged individually to receive radiotherapy to all sites of metastases where feasible.

Definition of Radiotherapy Target Volumes for Metastases

Radiotherapy should be delivered to the metastases at the same time as primary treatment, but may be delivered sequentially where large volumes of the body require to be irradiated.

The GTV for metastases, will be defined as gross extent of metastasis at presentation on CT, PET and/or MRI. These will be named as per the International Naming Convention in the AAPM TG 263 report, and is detailed in the FaR-RMS Quartet RTQA Guidelines. In case of discrepancy between imaging modalities, the larger volume should be delineated.

Margins for metastatic sites from GTV to CTV: 5 to 10 mm.

For exceptional cases with bulky macroscopic residual metastatic disease post induction chemotherapy margins from GTVmetastasis_post to CTVmetastasis_post should be 5 mm.

Expansion from the CTVs (or ITVs) to PTVs is to be undertaken as per local standard of care, based on the specific radiotherapy technique, image guidance strategy and set up errors, and is usually in the range of 3 to 10 mm.

Dose Prescription and Dose Fractionation for metastases

Radiotherapy dose and fractionation for specific sites is detailed in the FaR-RMS Radiotherapy and Imaging Manual, including fractionated radiotherapy for localized metastases, stereotactic ablative intracranial or body radiotherapy (for patients with limited metastatic disease only), whole lung, whole abdomen and whole brain. For the majority of metastases the intention will be to treat to an equivalent radiotherapy dose as detailed below.

- **Favourable metastatic disease** = Metastatic radiotherapy 41.4Gy in 23 fractions over 4.5 weeks (or equivalent)
- **Unfavourable metastatic disease** = Metastatic radiotherapy 41.4Gy in 23 fractions over 4.5 weeks (or equivalent)
- **Unfavourable metastatic disease** = No metastatic radiotherapy (radiotherapy only to primary tumour and involved regional lymph nodes).

- For bulky residual macroscopic metastatic disease only, where an initial Phase 1 of 41.4Gy in 23 fractions over 4.5 weeks (or equivalent) is to be delivered, Phase 2: 9Gy in 5 fractions (or equivalent) to PTVmetastasis_post.

Specific guidelines for metastatic radiotherapy:

- For bone, nodal and soft tissue metastases at other sites, 41.4Gy in 23 fractions or equivalent will be given.
- For one or more lung metastases, whole lung radiotherapy is given. The usual dose will be 15 Gy in 10 fractions.
- In cases of small volume and limited metastatic disease (≤ 3 metastases) stereotactic ablative body radiotherapy (SBRT) may be considered.
- In cases of malignant ascites, or diffuse peritoneal involvement, whole abdominal radiotherapy should be considered. The usual dose will be 24 Gy in sixteen fractions (or equivalent), followed by a boost to the primary tumour site (where identifiable) up to a dose of 41.4Gy (microscopic disease) or 50.4Gy (macroscopic disease).
- For patients with only limited brain metastases, where pre-treatment scans show a tumour volume $\leq 20\text{cc}$, and no individual tumour with a diameter $>3\text{cm}$, these may be considered for stereotactic radiotherapy (SRT).
- Whole brain radiotherapy may be considered for multiple brain metastases not suitable for SRT; the usual dose will be 30 Gy in 10 fractions.
- For lung only metastases with small volume and limited macroscopic residual metastatic disease, SBRT can be considered, in addition to whole lung RT and so doses should be adjusted to take this into account. Such exceptional cases should be discussed with the QUARTET RTQA experts.

Please see FaR-RMS Quartet RTQA Guidelines document for further details on the delineation, margins, radiotherapy techniques and Organ at Risk (OAR) dose constraints.

Radiotherapy Toxicity and Dose Modifications

All toxicity should be managed as per institutional practice/standard of care.

All dose delays and modifications should be managed as per institutional practice/standard of care however unscheduled interruptions to radiotherapy treatment should be avoided.

Radiotherapy supportive care

During radiotherapy patients should receive skin care, blood product support/ GCSF, antiemetics and analgesia when required as per local institutional guidelines.

2- EpSSG non-rhabdomyosarcoma protocol

14 Radiotherapy guidelines

Radiotherapy is an essential component of the treatment strategy for NRSTS.

The use of radiotherapy is a balance between the prognostic improvement due to radiotherapy and the potential side effects of the treatment. In adults, radiotherapy is required in most patients after wide excision, especially in large tumours, and irradiation is considered always unnecessary only after compartment resection. The situation in children and adolescents is different: the morbidity of radiotherapy is clearly much greater than in adults (depending on the site that require irradiation) since these patients are growing and physical development can be disturbed.

In adult studies, relatively high total dose of conventional fractionated external beam irradiation are recommended to achieve local control: doses of 60-64 Gy are used, sometimes with 50 Gy on a large first volume and a boost on a smaller one. Radiotherapy is usually delivered following surgery (post-operative radiotherapy), but excellent results have been reported with pre-operative irradiation. For children and adolescents, so far lower radiation doses of about 50 Gy have been used in the CWS-trials.

The rationale, indications and doses of radiotherapy in synovial sarcoma and adult type NRSTS are given below.

14.1 Equipment

► Megavoltage equipment

All patients will be treated with megavoltage equipment (4-20 MV linear accelerator preferably). For extremity tumours photons of 4 to 6 MV are recommended. Care must be taken to ensure an adequate skin dose in high risk areas when high energy photons are used. For tumours of the trunk, photons of 6 to 20 MV energy are recommended.

► Electrons

Electrons are allowed for superficial and moderately infiltrating tumours (to a maximum depth of 5 cm) either as an electron field matching on, or as boost to, linear accelerator planned fields. The use of electron fields alone should be avoided because of the late effects.

► Brachytherapy

Brachytherapy may be used in cases of incompletely resected tumours of vagina, perineum, bladder, prostate and orbit. It may be used as boost technique before or after external beam irradiation or may in some cases replace external beam irradiation. This must be discussed with the reference centre for each individual patient. The dose for brachytherapy and external beam radiotherapy must take into account radiation-tolerance of adjacent tissue and should be calculated individually in each case.

14.2 Treatment planning

3-D-conformal radiotherapy planning is recommended when critical structures lie in or nearby the

target volume. The dose is prescribed according to ICRU 50.

14.3 Fractionation

Treatment is applied in **conventional fractionation with 1.8 Gy per day, 5 day per week**. In patients with large fields, smaller fractions may be used. In patients < 3 years of age, smaller fractions may be given as well (1.6 Gy). The radiation dose is prescribed according to ICRU 50.

►►► Compensation for treatment breaks

Standard fractionation is 5 days per week. If there is a treatment interruption, 2 fractions with an interval of at least 6 hours between fractions should be given to enable completion of treatment within the same overall time, if 51mprove51 from the surrounding critical structures.

14.4 Target volume definition for primary tumour

▣ The target volume is chosen according to the initial tumour volume (gross tumour volume – GTV). The pre-therapeutic T1 MRI image with contrast is usually the optimal imaging study.

_ Exceptions: intrathoracic or pelvic tumour bulk

▣ The clinical target volume (CTV) is defined as the GTV + 1 cm

_ Exception limbs: 2 cm in longitudinal direction

▣ Additionally, scars of the biopsy, of the initial surgery, of the second look surgery and of drain sites have to be included in the CTV. Furthermore all tissues that were potentially tumour-contaminated during surgery need to be included in the CTV.

▣ The planning target volume (PTV) is defined as the CTV + 1 cm

_ Exception chest wall: 2 cm

▣ In patients receiving a boost after 50.4 Gy, the PTV of the boost is the residual tumour at the start of radiotherapy plus a margin of 1-2 cm.

▣ In growing patients, a radiation dose gradient through the epiphyseal growth plates should be avoided because of the risk of asymmetric growth. The growth plates should either be included in or, if feasible from the tumour extension, be excluded from the radiation fields.

The same should be observed for vertebral bodies in order to avoid scoliosis.

Summary:

The PTV consists of the initial tumour volume + 2 cm except for limb and chest wall tumours (+ 3 cm). Areas contaminated during surgery including scars and drainage sites must be included in the PTV. If more than 50.4 Gy need to be applied, the PTV of the boost is the residual tumour at the start of radiotherapy plus a margin of 1-2 cm.

14.5 Target volume definition for lymph nodes

In case of involved lymph nodes:

122. Radiotherapy could be avoided in case of radical lymphadenectomy (surgical removal of all the lymph nodes of the involved site).

122. After biopsy or non-radical resection (surgical removal of the involved nodes but not of all the lymph nodes of the involved site) radiotherapy is required. The dose of **50.4 Gy** is applied to the

entire lymph node site (axilla, groin, paraaortic lymph nodes etc.). When that approach results in very large radiation fields, this extent can be reduced to the involved lymph nodes plus a PTV margin of 3 cm at the discretion of the treating radiation oncologist.

122. In case of still enlarged lymph nodes at the time of radiotherapy, lymph nodes receive an additional boost up to a total dose of **59.4 Gy** if feasible from the surrounding critical structures (PTV definition for the boost as for the boost of primary tumour).

If possible the draining lymphatic vessels between the primary tumour and the involved lymph node site should be irradiated. However, in some cases this would result in unacceptable large radiation fields. In these patients, two separate radiation fields have to be used to treat the primary tumour and the lymph node site excluding draining lymphatic vessels.

14.6 Timing of radiotherapy

Since the value of chemotherapy is not clear, radiotherapy should not be delayed when radiotherapy and chemotherapy are given.

In patients submitted to initial gross resection, radiotherapy should start at least after 3 cycles of chemotherapy. Radiotherapy plans should be performed during the 7th week, with the aim to start the irradiation at **week 9**, at the resolution of the toxicity of the third cycle of chemotherapy.

During the administration of radiotherapy (5-6 weeks, overlapping with 2 chemotherapy cycles) chemotherapy will be given with ifosfamide alone.

In patients with IRS group III (macroscopical residual disease), the option for second surgery must be checked before the onset of radiotherapy.

In patients receiving **no second surgery**, radiotherapy is performed at **week 9**.

When second surgery is planned, there are 3 treatment options:

- preoperative radiotherapy
- postoperative radiotherapy
- no radiotherapy

When radiotherapy is performed before second surgery (**pre-operative radiotherapy**), irradiation starts at **week 9**. Surgery should be performed 5 weeks after the end of radiotherapy (and after the last chemotherapy cycle) to avoid surgical complications.

When **postoperative radiotherapy** is given, radiotherapy should be started within 21 days except when there are postoperative complications.

14.7 Indications and doses

► Synovial sarcoma:

IRS group I _ no RXT

IRS group II ≤ 5 cm _ 50.4 Gy (1.8 Gy/d)

> 5 cm _ 54 Gy (1.8 Gy/d)

* RXT could be avoided in selected cases (i.e. age < 10 years)

IRS III

different options in relation to delayed surgery
(and to age and initial tumour size)

_ no RXT

English version 3.0

- _ pre-op RXT 50.4 Gy
- _ post-op RXT 50.4 Gy ("R0")
- _ post-op RXT 54 Gy ("R1")
- _ definitive RXT 59.4 Gy

► **Adult type NRSTS:**

IRS group I ≤5 cm _ no RXT

> 5 cm **G1** _ no RXT

G2 _ RXT 50.4 Gy

G3 _ RXT 50.4 Gy

IRS group II G1 _ no RXT

G2 _ 54 Gy

G3 _ 54 Gy

IRS III

different options in relation to delayed surgery
(and to age and initial tumour size)

- _ no RXT
- _ pre-op RXT 50.4 Gy
- _ post-op RXT 50.4 Gy ("R0")
- _ post-op RXT 54 Gy ("R1")
- _ definitive RXT 59.4 Gy

14.8 Normal tissue tolerance guidelines

Conventional fractionation

(F: fraction)

Heart **30.6** Gy; 17 F

whole liver **19.8** Gy; 11 F

whole kidney **14.4** Gy; 8 F

spinal cord (part)

spinal cord in pts. With residual paraspinal tumour (on MRI)

41.4 Gy; 23 F

50 Gy; 28 F

optic nerve/optic chiasm **45** Gy; 25 F

14.9 Treatment guidelines for special sites

Parameningeal tumours

In case of skull base erosion and cranial nerve palsy, the PTV will be that required to treat the primary tumour (initial tumour volume + 2 cm). Radiation fields must adequately cover the initial skull base erosion but there is no routine whole brain irradiation.

Extremities

Extremity tumours should be treated according to the general guidelines described above. Tissue

contaminated during surgery must be included in the CTV. After surgical procedures, all scars and drainage sites should be irradiated with a safety margin of 1 – 2 cm. Circumferential radiotherapy must be avoided because of the danger of constrictive fibrosis and lymphedema. In growing patients, a radiation dose gradient through the epiphyseal growth plates should be avoided because of the risk of asymmetric growth. The growth plates should either be included in or, if feasible from the tumour extension, be excluded from the radiation fields.

Urogenital Site

The doses and target volume definitions follow the general guidelines. Gonads should be positioned out of the treatment volume if possible (in girls oophoropexy must be discussed!). Individual planning and discussion with the respective reference centre is advised.

Abdomen

The kidney and liver tolerance doses have to be respected. In growing patients, a radiation dose gradient through vertebral bodies should be avoided because of the risk of scoliosis. Vertebral bodies and pedicles should either be included in or, if feasible from the tumour extension, be excluded from the radiation fields.

Pelvis

Small bowel/iliocaecal bowel may be displaced from the pelvis by treating the patient in prone position and by using a belly board. In some cases, bowel can be spared with special surgical techniques using a spacer. Tumours with non-infiltrating extension into the preformed pelvic cavity often show a large intrapelvic mass. Irradiating the pre-treatment volume would mean that large volumes of normal tissue (bowel and bladder) are in the radiation field. In these cases, the target volume in the areas of non-infiltrating tumour encompasses only the residual mass after surgery/chemotherapy at the beginning of radiotherapy and a 2 cm safety margin. For all other parts of the tumour (infiltrated muscle, bone or organs), the general safety margins according to the initial tumour extension are to be applied.

Retroperitoneum

Tolerance doses of organs in this region need to be respected (i.e. kidneys, bowel, spinal cord). Dose volume histograms for these organs are strongly recommended. In order to avoid scoliosis in growing patients the vertebral bodies should either be irradiated symmetrically or shielded.

Chest wall

The doses and target volume definitions follow the general guidelines. Tumours with noninfiltrating extension into the preformed thoracic cavity often show a large intrathoracic mass. Irradiating the pre-treatment volume would mean that large volumes of lung tissue are in the radiation field. In these cases, the target volume in the areas of non-infiltrating tumour encompasses only the residual mass after surgery/chemotherapy at the beginning of radiotherapy and a 3 cm safety margin. For all other parts of the tumour (infiltrated muscle or bone), the general safety margins according to the initial tumour extension are to be applied.

14.10 Quality assurance of radiotherapy

Radiotherapy documentation forms will be completed and submitted via the relevant data office for English version 3.0

review by the Radiotherapy Committee. Simulator films, plans and diagnostic films which determined treatment volume will be requested in all cases who fail locally after radiotherapy and in randomly selected cases of those who do not fail as part of a quality assurance assessment. This will be co-ordinated by the Radiotherapy Committee who will contact centres for films from individual patients as requested.

References

- Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. *J Clin Oncol* 16:197-203, 1998
- Coindre JM, Terrie P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma : a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. *J Clin Oncol* 14:869-877, 1996
- DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft tissue sarcomas. *Int J Radiat Oncol Biol Phys.* 2003; 56:1117-1127
- O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomized trial. *Lancet* 2002;359:2235-2241.
- Khanfir K, Alzieu L, Terrier P, et al. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremity ? *Eur J Cancer* 2003;39:1872-80.
- Geer RJ, Woodruff J, Casper ES, Brennan MF. Management of small soft-tissue sarcoma of the extremity in adults. *Arch Surg* 1992;127:1285-9.
- Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremity and trunk. *J Clin Oncol* 1999;17:3252-9.
- Cormier JN, Langstein HN, Pisters PW. Preoperative therapy for soft tissue sarcoma. *Cancer Treat Res* 2004;120:43-63.
- Ward I, Haycocks T, Sharpe M, et al. Volume-based radiotherapy targeting in soft tissue sarcoma. *Cancer Treat Res* 2004;120:17-42.
- Schuck A, Mattke AC, Schmidt B, et al. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? *J. Clin. Oncol.* 22(1), 143-149 (2004).
- Wolden SL, Anderson JR, Crist WM, et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. *J. Clin. Oncol.* 17, 3468-3475 (1999).
- Viswanathan AK, Grier HE, Litman HJ et al. Outcome for 55 improve55 with group III rhabdomyosarcoma treated with or without radiotherapy. *Int. J. Radiation Oncology Biol. Phys.* 58(4), 1208-1214 (2004).

Synovial sarcoma

17.2 Radiotherapy

Concerning radiotherapy, as for other STS, it will be given as conventional fractionation of 1.8 Gy/day. The total dose will range between 50.4 and 59.4 Gy.

► IRS Group I (initial complete resection, R0):

The INT Milan series seemed to suggest a favourable trend for post-operative radiotherapy in patients previously submitted to complete resection (with no statistically significant difference).

Post-operative radiotherapy

yes no

5 year LRFS complete resection (n.patients 144) 77.8% (n.51) 66.9% (n.93)

complete resection, tumour ≤ 5 cm (n.63) 100% (n.19) 75.9% (n.44)

complete resection, tumour > 5 cm (n.72) 73.1% (n.30) 60.9% (n.42)

5 year LRFS marginal resection (n.71) 57.4% (n.56) **7.1%** (n.15)

EpSSG NRSTS 2005 protocol

62

In the common ICG-CWS analysis, no benefit of adding radiotherapy in IRS group I patients (complete macroscopic and microscopic resection) was observed, independent on the initial tumour size. So far there is no clear evidence of the role of radiotherapy in these patients. Since large initial tumour size is a recognized risk factor stopping rules for local failures for patients with tumours larger than 5 cm in diameter at diagnoses will be defined.

► IRS group II (microscopic residual disease at initial resection or positive lymph nodes):

Important note:

Every effort should be done by the surgeon to avoid IRS group II patients (the use of primary reexcision is recommended, when feasible).

In the CWS-ICG-analysis, the treatment results for patients in IRS group II were comparable to those in IRS group I. These results were obtained with nearly all patients in IRS II receiving radiotherapy.

The multicenter analysis from the M.D. Anderson (*Okcu F, J Clin Oncol 2003*) showed the benefit of post-operative radiotherapy on LRFS and OS in group I-II patients.

In the analysis of the INT Milan data, a clear benefit was observed for group II patients who received radiotherapy: 5-year LRFS was 7% in the 15 group II patients treated without irradiation. This series regards patients of all ages, mainly adults (*Ferrari A, Cancer 2004*).

These findings would suggest the use of radiotherapy after marginal resection.

In the cohort of 66 paediatric patients with synovial sarcoma enrolled in the SIOP MMT 84-89-95 studies, 22 patients initially submitted to microscopically incomplete resection were seen. All of them received chemotherapy (IVA), while radiotherapy was given to 5 patients only (17 did not receive radiotherapy).

Local relapses were seen in 1/5 patients treated with radiotherapy (then the child was salvaged with second-line therapy).

Among the 17 patients treated without irradiation, 3 patients had local relapse and 2 had metastatic

relapse: 1 out of the 3 local relapsing patients and 1 of the patients who developed metastases died of their disease; at the end, 20/22 IRS group II patients were alive in first (16) or second (4) remission at the time of the analysis.

Concerning radiotherapy, 12 patients with initial microscopically incomplete resection were cured without radiotherapy, and therefore without radiotherapy-related side effects.

These findings may suggest that radiotherapy could be avoided in some IRS group II patients, at least those with younger age and small tumour size.

The debate on indication for radiotherapy in IRS II patients has its background on the different philosophies adopted over the years by the CWS-ICG groups and the SIOP group. It is important to underline the concept of the “total burden of therapy” experienced by a given patient and the predicted sequelae that treatments may have. In particular, the philosophy behind the SIOP-MMT studies has pointed to a lesser use of radiotherapy in selected subsets of patients, i.e. children submitted to marginal resection at diagnosis, with suspected microscopical residual disease: this strategy generally produced worse local relapse rates than those reported elsewhere, but the overall survival was superimposable, since a significant number of locally relapsing patients were cured by salvage treatments (including aggressive surgery and radiotherapy); on the other hand, a significant proportion of patients could be cured without radiotherapy. In other words, according to this strategy, outcome should be measured on the combination of overall survival and “cost” of survival in terms of sequelae, rather than on disease-free survival alone.

EpSSG NRSTS 2005 protocol

63

This is yet matter of debate.

The EpSSG NRSTS 2005 protocol will suggest the use of **radiotherapy in IRS group II** synovial sarcomas (as required by ICG-CWS groups), but an **alternative option** may be to avoid irradiation, in particular for younger patients (age less than 10 years) and tumour size smaller than 5 cm (SIOP option). The multidisciplinary discussion may determine the decision in individual case.

Radiotherapy will be applied in conventional fractionation. The total radiation dose for patients with tumours < 5 cm in diameter is **50.4 Gy** in 1.8 Gy fractions. Because of a higher local failure risk in patients with larger tumours, **54 Gy** are given in patients with > 5 cm initial tumour size. In order to avoid concomitant administration of doxorubicin and radiotherapy (that will last 5-6 weeks, overlapping with 2 chemotherapy cycles), in group II ≤ 5 cm patients (3 cycles of chemotherapy required), radiotherapy will start after the completion of the 3 chemotherapy cycles, avoiding the need of concomitant chemo-radiotherapy.

In group II > 5 cm, radiotherapy cannot be delayed at the end of chemotherapy (18th week).

Therefore, radiotherapy will start at 9th week and will be administered concomitantly to 4th and 5th cycles of chemotherapy (ifosfamide alone)

► **IRS group III (macroscopic residual disease at initial resection):**

After the initial 3 cycles of chemotherapy, tumour-reassessment and then local treatment need to be planned.

Four different options are possible:

122. Patients with the option of secondary complete resection:

Surgery remains the mainstay of treatment for synovial sarcomas.

The use of radiotherapy is a matter of debate in patients with secondary complete resection.

In the CWS group, nearly all patients treated with complete second surgery received radiotherapy.

In INT Milan series, 30 out of 40 IRS group III patients had delayed complete resection: 11 of them received radiotherapy, 19 did not, and no difference was observed on the outcome. Survival rates strongly correlated with the chances to achieving complete surgery (5-year EFS 42% vs 10%), though metastases (and not the local relapse) were the main cause of treatment failure (5-year LRFS 80%, MFS 34%) (*Ferrari A, Cancer 2004*).

In the EpSSG centers, there is no a consensus on:

- 122) the necessity to give radiotherapy after delayed complete surgery; it is not clear whether the use

of radiotherapy in these patients results in improved survival

- 122) what is the best option, when the decision to give radiotherapy has been taken, between preoperative

and post-operative radiotherapy

(pre-operative irradiation can improve the chance to perform a complete secondary resection; moreover, pre-operative radiotherapy could be more effective in non-hypoxic tissues, may reduce the risk of intra-operative contamination, and could use smaller radiotherapy fields; post-operative radiotherapy has a small risk of wound complication).

Therefore, there are three treatment options for patients with the option of secondary complete resection:

a1. Preoperative RXT with 50.4 Gy in 1.8 Gy daily fractions

EpSSG NRSTS 2005 protocol

64

a2. No additional RXT following secondary complete resection

a3. Postoperative RXT with 50.4 Gy in 1.8 Gy daily fraction

The decision may depend also to the physician's preference.

However, possible suggestions are:

- to avoid RXT in younger patients after delayed complete surgery (< 6 years)
- to give RXT in case of initial large tumour size (> 10 cm) and in case on first surgical approach (biopsy) that could have caused tissue contamination.

The results of the different local modality groups will be compared

a.4 Following secondary incomplete resection, **54 Gy** have to be given with microscopical residual disease. In case of macroscopic residual disease, radiotherapy has to be given according to patients with no second surgery (see below)

b. Patients without the option of secondary complete resection:

IRS group III patients who cannot have a complete secondary resection have a poor prognosis and need to have radiotherapy. Radiotherapy is then the only local therapy modality and should be given with high doses. The recommended dose is **59.4 Gy**.

An additional boost of 5.4 Gy can be given when there is residual disease at the end of radiotherapy. The dose recommendation may need modification depending on the age of the patient and the tumour site.

Timing of radiotherapy

IRS group II:

Radiotherapy should start after 3 cycles of chemotherapy. Radiotherapy plans should be performed during the 7th week, with the aim to start the irradiation at **week 9**, at the resolution of the toxicity of the third cycle of chemotherapy.

During the administration of radiotherapy (5-6 weeks, overlapping with 2 chemotherapy cycles) chemotherapy will be given with ifosfamide alone (patients with tumour > 5 cm).

IRS group III:

The option for second surgery must be checked before the onset of radiotherapy.

In patients receiving **no second surgery**, radiotherapy is performed at **week 9**.

When second surgery is planned, there are 3 treatment options:

- preoperative radiotherapy
- postoperative radiotherapy
- no radiotherapy

When radiotherapy is performed before second surgery (**pre-operative radiotherapy**), irradiation starts at **week 9**. Surgery should be performed 5 weeks after the end of radiotherapy (and after the last chemotherapy cycle) to avoid surgical complications.

When **postoperative radiotherapy** is given, radiotherapy should be started within 21 days except when there are postoperative complications.

► ► ► Radiotherapy in younger children

Children < 3 years of age

Radiotherapy is only given when there is residual tumour after primary or secondary resection. For patients in IRS group III without an option of secondary complete resection, the dose is reduced to 50.4 Gy

- IRS group I: no RXT
- IRS group II: no RXT
- IRS group III, secondary complete resection: no RT
- IRS group III, no secondary surgery: 50.4 Gy

Adult type STS

18.2 Radiotherapy

► IRS Group I (initial complete resection, R0):

In adult patients with soft tissue sarcoma, radiotherapy is required after incomplete resection, but

often also after wide excision, especially in case of large tumour. In children with a higher risk of severe late effects of radiotherapy, the indication has to be stricter than in adults.

There is little data about the impact of radiotherapy in IRS group I patients in paediatric age. In the analysis of the St. Jude's experience of patients with at least grossly resected tumours, univariate analysis of factors associated with improved local control included the use of radiotherapy. It is of note, though, that the majority of irradiated patients belonged to IRS group II. (*Spunt S, 2002*).

In the INT Milan series, 100 paediatric patients were classified as IRS group I: 22 received postoperative radiotherapy and 78 did not. LRFS at 5 years was 95.2% in the group of patients who had radiotherapy and 84.4% in the second group, without statistically significant difference. When only patients with tumour larger than 5 cm were considered, 5-year LRFS and OS were 91.7% and 90.0% for patients treated with radiotherapy (13 cases) and 69.8% and 53.8%, respectively, for those who were not irradiated (23 cases), and the p value was significant for OS (though the OS results may be influenced by the different use of chemotherapy in this two groups, the percentage of patients who had also chemotherapy being higher in the first group) (*Ferrari A, J Clin Oncol 2005*).

However:

- because of the low risk of local failure in patients with small tumours, no radiotherapy is given in patients in IRS group I with < 5 cm tumour diameter at diagnosis.

- in IRS group I patients with tumours > 5 cm, radiotherapy is given in G2 and G3 tumours (no in G1 tumour). In case of local relapses, these patients are at risk of metastatic relapse and consequently impaired prognosis. The radiation dose of adjuvant radiotherapy is **50.4 Gy** in 1.8 Gy fractions.

► **IRS group II (microscopic residual disease at initial resection):**

Patients with microscopic residual disease following secondary complete resection are at a considerable risk to develop local recurrences. In the INT Milan series, 5-year LRFS was 75.7% in patients who had radiotherapy (n = 27) and 55.6% in those who did not receive it (n = 9) (*Ferrari A, J Clin Oncol 2005*).

An exception is low-grade tumours. The risk of relapse is lower, and furthermore local recurrences are usually again low-grade, are hardly ever associated with systemic failure, and could be treated with success with re-surgery and eventual radiotherapy. COG (Children's Oncology group) series included 4 IRS group II G1 patients treated without radiotherapy who did not relapse (*unpublished data*). In the INT Mila series, 3 patients were classified as group II/G1: two received radiotherapy, and one did not; this patient relapsed locally, but he was salvaged with surgery and radiotherapy. Therefore, no radiotherapy is recommended in patients with IRS group II G1 tumours.

An exception is patients in whom surgery of local recurrence would be problematic because of tumour site or because of the extent of primary surgery. In these cases, radiotherapy should be given at primary treatment (54 Gy).

In patients IRS group II G2-3, radiotherapy is given with **54 Gy**, 1.8 Gy daily fractions.

IRS group III (macroscopic residual disease at initial resection):

As for synovial sarcoma, after the initial 3 cycles of chemotherapy, tumour-reassessment and then

local treatment need to be planned.

122. **Patients with the option of secondary complete resection:**

Patients with initially unresectable tumour are at high risk of local failure. In the St. Jude's experience, local failure rate was 44 % at 5 years (*Spunt S, 2002.*). The mainstay of treatment is to obtain a secondary complete resection. Initial incomplete resection should be followed by immediate re-resection if expected to be complete and non-mutilating. In all other patients, chemotherapy is administered before second surgery is attempted. The use of radiotherapy is a matter of debate in patients with secondary complete resection. In the paediatric series from the INT Milan, the 5-year OS of the 40 group III patients was 52%, and correlated with the chance to undergo delayed surgery with histologically free margins. No major differences were observed according to the administration of post-operative radiotherapy: 5-year OS was 80% in the 11 patients who had delayed complete surgery alone, and 86% in the 8 patients who had delayed complete surgery followed by radiotherapy (*Ferrari A, J Clin Oncol 2005*).

Similarly to IRS group III synovial sarcomas, there is no a consensus about a common approach concerning radiotherapy, in particular on:

- 1) the necessity to give radiotherapy after delayed complete surgery
- 2) what is the best option, when the decision to give radiotherapy has been taken, between preoperative and post-operative radiotherapy

(pre-operative irradiation can improve the chance to perform a complete secondary resection; moreover, pre-operative radiotherapy could be more effective in non-hypoxic tissues, may reduce the risk of intra-operative contamination, and could use smaller radiotherapy fields; post-operative radiotherapy has a small risk of wound complication).

Therefore, there are three treatment options for patients with the option of secondary complete resection:

- a1.** Preoperative RXT with **50.4 Gy** in 1.8 Gy daily fractions
- a2.** No additional RXT following secondary complete resection
- a3.** Postoperative RXT with **50.4 Gy** in 1.8 Gy daily fraction

The decision may depend also to the physician's preference.

However, possible suggestions are:

- to avoid RXT in younger patients after delayed complete surgery (< 6 years)
- to give RXT in case of initial large tumour size (> 10 cm) and in case on first surgical approach (biopsy) that could have caused tissue contamination.

The results of the different local modality groups will be compared

- a.4** Following secondary incomplete resection, **54 Gy** have to be given with microscopical residual disease. In case of macroscopic residual disease, radiotherapy has to be given according to patients with no second surgery (see below)

b. Patients without the option of secondary complete resection:

Radiotherapy is then the only local therapy modality and should be given with high doses. The recommended dose is **59.4 Gy**. An additional boost of 5.4 Gy can be given when there is residual

disease at the end of radiotherapy. The dose recommendation may need modification depending on the age of the patient and the tumour site.

►►► Timing of radiotherapy

IRS group I (> 5 cm) and group II:

Radiotherapy (when indicated) should start after 3 cycles of chemotherapy. Radiotherapy plans should be performed during the 7th week, with the aim to start the irradiation at **week 9**, at the resolution of the toxicity of the third cycle of chemotherapy.

During the administration of radiotherapy (5-6 weeks, overlapping with 2 chemotherapy cycles) chemotherapy will be given with ifosfamide alone.

IRS group III:

The option for second surgery must be checked before the onset of radiotherapy.

In patients receiving **no second surgery**, radiotherapy is performed at **week 9**.

When second surgery is planned, there are 3 treatment options:

- preoperative radiotherapy
- postoperative radiotherapy
- no radiotherapy

When radiotherapy is performed before second surgery (**pre-operative radiotherapy**), irradiation starts at **week 9**. Surgery should be performed 5 weeks after the end of radiotherapy to avoid surgical complications. The sixth cycle of chemotherapy should be given after the end of radiotherapy and before surgery, the last cycle after surgery.

When **postoperative radiotherapy** is given, radiotherapy should be started within 21 days except when there are postoperative complications.

►►► Radiotherapy in younger children

Children < 3 years of age

IRS group I independent of size: no RXT


IRS group II G1: no RXT

IRS group II G2 and G3: 50.4 Gy


IRS group III and delayed complete resection no RXT

IRS group III, no second surgery possible: 50.4 Gy


Appendix 4 – Flow chart

Flowchart – Guidelines

Flowchart – Primære studier



Rt in soft tissue sarcoma



Flowchart: Literature included in version 1.3.

Appendix 5 – Evidence table

DSG	Retningslinjens emne/titel: Radiotherapy of localised soft tissue sarcoma							
Forfatter/ kilde	År	Undersø- gelses- type/des ign	Und- er- søge I- sens kval itet jf. Oxfo rd	Intervention	Sammenlign- ings intervention	Patient- population	Resultater (outcome)	Kommentarer
Gerner RE et al.	1975	retrospect ive	2b	surgery	amputation vs. local therapy	limb	Amputation gives better local control	155 pt.
Lindberg RD et al.	1981	retrospect ive	2b	surgery + postop. Rth		all sites	Good local control	300 pts

Rosenberg SA Et al.	1982	prospective	1b	surgery and radiotherapy	amputation vs. local surgery + Rth	limb	Equal results of the 2 strategies	43
Yang et al.	1998	prospective	1b	LSS + surgery vs. surgery	LC	limb	Rth improve LC but not OS	141 both high (91) and low grade (50)
Beane JD et al.	2014	prospective	1b	adj. rth	surgery vs. surgery + rth	limb	Rth improve local control	No survival benefit, 141 pts
Pisters PW et al	1996	prospective	1b	adj. Rth	Surger vs. surgery + rth	limb and trunk	Rth improves local control	164 pts. Brachytherapy
Harrison LB et al.	1993	prospective	1b	adj. rth	Surgery vs. surgery + rth	limb and trunk	Rth gives durable local control	126 pt. Brachytherapy
Italiano A	2014	database	2c	adj therapy		all sites	Rth improves local control	3255 pts
Jebsen NL et al.	2008	database	2c	adj. rth		trunk and limb	Rth 67mprove LC	1093
Casali PG et al.	2018	guidelines	2c	adj. Rth		all sites		ESMO
Rydholm A	1991	retrospective	2b	superficial STS	surgery ± Rth	limb abd trunk	Rth could be omitted	129

Tsagozis P et al	2015	database	2c	superficial STS	Surgery ± Rth	limb and trunk	Surgery is 1.ry ttt	622
Larrier NA et al	2016	review	2b	superficial and deep	Surgery and Rth	all sites		
Strander H et al	2003	review	2b	superficial and deep	Surgery and Rth	all sites		4579
Pisters PW	2007	review	2b	superficial and deep	Surgery and rth and cth	all sites		
Alektiar KM et al.	2000	retrospective	2b	+ve margin	LC	limb	Rth improve LC but inferior to -ve margin	110
Tang YW et al.	2012	retrospective	2b		Margins & recurrence	all sites	Rth is not substitute for surgery	73 pts
Choong PF et al.	2001	retrospective	2b	low grade	LC	limb	Rth for close margin	132
Mollabashy A	2002	retrospective	2b	post op for low grade	LC	limb	No effect of Rth	108
Pisters PW et al.	2007	prospective	2b	Selective Rth	LC	limb and trunk	Rth for selected cases	88

Schreiber D et al.	2012	database	2c			limbs	Rth improve survival in T. >5cm	983 pts
Alektiar KM et al.	2002	retrospective	2b	<5cm	LC	limb	No effect of rth	204
Kepka L et al.	2005	retrospective	2b	radical rth.		All sites	Effective LC	112 pts
Weber DC et al.	2007	retrospective	2b	proton		parameningeal RMS	Good LC	39 pts
O'Sullivan B	2002	prospective	1b	pre vs. post	LC	limb	Pre = post	190
Davis AM et al.	2002	prospective	1b	pre vs. post	LC, physical function	limb	Pre = post	190 pts
Davis AM et al.	2005	prospective	1b	pre vs. post op.	Late effects	limb	More late effects with postop.	129 pts
Al-Absi E	2010	review	2b	preop. Rth	LC & mets rate	limb	Preop. Is safe and effective	1098
Sampath S et al.	2011	retrospective	2b		Pre vs. post	all sites	Better OS for preop.	821

Zagars GK et al.	2003	retrospective	2b	sequencing in reexcision	LC	all sites	Pre or post op. rth is possible with reexcision	295
Dagan R et al.	2012	retrospective	2b	preoperative rth		limb	Margina margin is enough	317 pts
Alamanda VK et al.	2014	retrospective	2b		Boost vs. no boost	limb	No effect of boost	94 pts
Al Yami A et al.	2010	retrospective	2b			positive margin	No advantage of boost	216 pts
Fourquet J, et al.	2016	retrospective	2b	time interval	Different intervals	STS	Interval doesn't affect outcome	1131 pts
Merimsky O, et al.	2005	retrospective	2b	Post-op.		Limb	feasible	133 pts
Ballo MT, et al.	2004	retrospective	2b	interval	LC		Interval didn't impact LC	799 pts.
Schwartz DL, et al	2002	retrospective	2b	delay in post op.	LC	trunk and limb	Inferior results in >4 months	102

Julie Chu et al.	2013	guidelines	A	evidence based	LC and survival	All sites	Preoperative dose	australian
Jebsen NL et al.	2015	guidelines	A	evidence based	LC and survival	All sites	Preoperative dose	scandinavian
NCCN	2018	guidelines	A	Evidence based	LC and survival	All sites	Preoperative dose	amedican
Pollack A, et al.	1998	retrospect ive	3b	Pre and post op. rth	LC	All sites	50 Gy post op. is not enough. Individual selection for pre or post	453
Jebsen NL, et al.	2013	retrospect ive	2b	Postoperative dose	LC	Trunk and limb	No dose reposne	462
Levy A, et al.	2018	retrospect ive	2b	Postop rth	Different doses	Limb STS	Dose escalayion is safe	Dose determined by expert MDT
Zagars GK, et al.	2003	retrospect ive	2b	Post op. dose	LC	All sites	Better LC with doses>60 Gy for high risk	775 pts.
Wolfson AH, et al.	1998	retrospect ive	3b	Dose response	survival	limb	Better survival with higher dose	59 pts

Dinges S et al	1994	retrospective	3b	Post op. dose	LC	All sites	Better LC with doses > 60 Gy	102
Delaney TF, et al.	2007	retrospective	2b	+ve margin		All sites	> 64 Gy for +ve margin	154
Kubicek GJ, et al.	2018	Phase II	2b	Preop-hypo-fractionation		STS different sites	Radical surgery is well tolerated	13 pts
Raval RR, et al.	2017	retrospective	3b	Cth + split course Rth		STS all sites	Split course + cth is effective	Only 16 pts
Soyfer V, et al.	2013	retrospective	3b	Hypo-fractionation		elderly	Hypofractionation is feasible	21 pts
Le Pechoux C, et al.	1999	retrospective	3b	hyperfractionation	LC	limb	Hyperfractionation is effective	62
Mundt AJ, et al.	1995	retrospective	2b	Margin to CTV	LC	limb	5cm margin is adequate	64
Kim B, et al	2010	retrospective	2b			Target definition		56 pts
Dickie CI	2012	retrospective	2b	Target volume	LC	Target definition	Recurrence in field	60 pts

Choi N et al.	2018	retrospective	2b	Post.op rth		Lower limb	Local recurrence in or close to Fluid collection	88 pt
Baldini EH et al	2015	guidelines	3b	Preop rth			Expert panel	
Tiong SS et al	2016	review	3b	role of rth	LC	All sites		
Haas et al	2016	review	3b	role of rth	LC	limb		
O'Sullivan B, et al.	2013	Phase 2	2b	IG-IMRT		limb	IG-IMRT reduce tissue transfer	70 pts
Alektiar KM, et al.	2007	retrospective	3b	IMRT		limb	IMRT give excellent LC	31 pts.
Alektiar KM, et al.	2008	retrospective	3b	IMRT		limb	IMRT give excellent LC	41 pts.
Lin C, et al	2012	Prospective, single arm	2b	IMRT		All sited	Better sparing of normal tissue	375 pts, Rhabdomyosarcoma
Stewart AJ et al	2009	retrospective	3b	IMRT post op.		limb	Better target coverage	10 pts.
Folkert MR, et al.	2014	retrospective	2b		IMRT vs. conventional	Limb STS	Less recurrence in IMRT	Good study 319 pts

Wang D, et al.	2015	Phase II	2b	IGRT	Compared with historical data	limbs	IGRT reduce late effects	No marginal failures
Smith KB et al	2011	retrospective	3b	Definitive Rth			Local failure is fatal	Non RMS, children and young adults
Bonvalot S. et al.	2020	prospective	1a	Surgery	LC free survival	retroperitoneal	No benefit of preoperative Rth.	266 pts
Cosper PF et al	2017	retrospective	2b	IMRT perioprtauive	LC	retroperitoneal	Excellent control	30 pts
Pawlik TM, et al.	2006	prospective	2b	Pre-op.	historical	retroperitoneum	Pre-op. gives better LC end hisorical	72
Kepka L et al	2012	retrospective	3b	Definitive rth	LC	Limb and retroperitoneal	Good control. Rth should be considered	112
Zlotecki RA, et al.	2005	retrospective	3b	Pre. Vs. post op.	LC-complications	retroperitoneum	Rth improve LC. Preop is better	40 pts.
Catton CN, et al.	1994	retrospective	2b	104	LC	retroperitoneum	Post op.rth dose of >35 Gy give longer PFS	104
Green WR, et al.	2018	database	2c	Adj. Rth		Non-retroperitoneal sarcoma	Adj. Rth improves OS in high grade pts	2832 pts

Reed NS et al	2008	Prospective phase III	1b	Adj rth vs. surgery	LC	Uterine sarcoma	No survival difference	224 pts
Sampath S et al	2010	retrospective	2c	Adj rth	LC	Uterine sarcoma	Rth imprve LC	2206 pts
Terek MC et al	2016	retrospective	2b	Adj rth	LC	Uterine sarcoma	Rth imprve LC	57 pts
Magnuson WJ et al	2015	retrospective	2b	Adj rth	LC	Uterine sarcoma	Rth imprve LC in stage I	157 pts
Sampath S and Gaffney DK	2011	review	2b	Role of rth	LC	Uterine sarcoma		
Livi L et al	2003	retrospective	2b	Role of rth	LC	Uterine sarcoma	Rth is indicated in stage I-III	141 pts
Le T	2001	retrospective	2b	Role of rth	LC	Uterine carcinosarcoma		32 pts
Ferrer F et al	1999	retrospective	2b	Adj rth	LC	Uterine sarcoma	Rth improve LC and PFS	103 pts
Yu T et al	2015	retrospective	2b	Adj rth	LC	Uterine sarcoma	Rth improve LC and PFS	75 pts

Weitmann HD et al	2001	retrospective	2b	Adj rth	LC	Uterine stromal sarcoma	Rth improve LC and PFS	21 pts
Malouf GG et al	2013	retrospective	2b	Role of rth	LC	Uterine sarcoma	Combined ttt strategy	29 pts
Philip CA et al	2014	review	2b	Role of rth	LC	Uterine sarcoma	Combined ttt strategy	
Linthout N et al.	2006	review	2b	Technical note				
Mahmoud O, et al.	2017	database	2c	Adj.rth		Head and neck STS	Adj Rth improves survival	788
Orbach D, et al.	2017	retrospective	2b	Adj.rth		H&N non-parameningeal RMS	Adj. improves survival and LC	140 (children)
Minard-Colin V, et al.	2013	retrospective	2b	<i>Cth+Rth+surgery</i>		<i>Head & neck sarcoma</i>	<i>Surgery + Rth is better than Rth alone</i>	<i>41 pts also children</i>
O'Sullivan B, et al.	2003	retrospective	3b	preop	LC	Head and neck	Less wound complication than limb and goos control	40 pts

Jang JH, et al	2012	retrospective	2b	surgery	LC	Breast phylloides sarcoma	Margin determine local recurrence rate	164
Barth RJ	1999	review	2b	surgery	LC	Breast phylloides	High recurrence rate with surgery alone	
Barth RJ et al.	2009	prospective	2b	Surgery + adj. rth	LC	Breast phylloides	Less recurrence after rth	46
Belkacemi Y et al	2008	retrospective	2b	Adj. rth	LC	Breast phylloides	Rth should be considered for high risk	443
Gnerlich JL et al	2014	database	2b	Adj rth	LC	Breast phylloides	Rth should be considered for high risk	3120
Kim YJ, and Kim K	2017	database	2b	Surgery + adj. rth	LC	Breast phylloides	Rth should be considered for high risk	1974
Ghareeb ER et al	2016	retrospective	2b	Surgery + adj. rth	LC	Breast angiosarcoma	Less recurrence after rth	35
Luini A et al	2007	review	2b	Surgery + adj. rth	LC	Breast angiosarcoma	Less recurrence after rth	

McGowan TS et al	2000	retrospective	2b	Surgery + adj. rth	LC	Breast sarcoma	Rth for microscopic disease	32
Barrow BJ, et al.	1999	retrospective	3b	Role of rth	LC	breast		59
Wolden S et al	1999	prospective	1b	Risk adapted combined tt	LC and survival	All sites		439 pts
Schuck A, et al.	2004	Prospective	1b	indication	LC	All sites	RTh is indicated in group II RMS	203
Arndt C et al	2001	Prospective	1b	indication	LC	Gynecolocal sites	RTh improves outcome	151
Martelli H et al	1999	Prospective	1b	indication	LC	Gynecolocal sites	RTh improve LC	38
Koscielniak E et al	2002	review	1b	indication	LC	all sites	RTh is indicated high and intermediate risk	
Regine WF et al	1995	Prospective	1b	Radiation dose	LC	all sites	At least 40 Gy	103
Donaldson SS, et al.	2001	prospective	1b	Hyperfractionation	Hyperfractionation vs. conventional Rth	Rhabdomyosarcoma	Hyperfractionation is as effective as conventional	Also children, 559 pts

Oberlin O et al	2001	prospective	1b	indication	LC and survival	Orbital RMS	Subset may not need rth	306
Schuck A et al	2004	prospective	1b	indication	LC and survival	All sites	Rth improves results of group II	203
Koscielniak E et al	2002	review	1b	indication	LC	all sites	RTh is indicated in group II RMS	
Suit H et al	2008	review	2b					
Miralbell R et al	2002	Case report/review	c	indication		Children all sites	normal tissue dose sparing advantage	2 pts
Hug EB et al	2000	Case report/review	c	indication		Children all site	normal tissue dose sparing advantage	2 pts
Weber DC et al	2004	Case report/review	c	indication		Children all site	normal tissue dose sparing advantage	5 pts
DeLaney TF et al	2009	Phase II	3b	indication	LC	Spine sarcoma	High LC	50 pts
Guttmann DM, et al.	2017	retrospective	2b	Re-irradiation		2ry or recurrent STS	Proton is safe as reirradiation	26 pts

Weber DC et al	2007	retrospective	2b	<i>indication</i>	LC	sarcomas	Spot scanning is effective and safe	13
Ladra MM et al	2014	retrospective	2b	<i>indication</i>	LC	Pediatric RMS	Lower integral dose	54 pts
Ladra MM et al	2014	Phase II	2b	<i>indication</i>	LC and survival	Pediatric RMS	Good LC and survival	57 pts
Childs SK et al	2012	retrospective	2b	<i>indication</i>	LC	Parameningeal pediatric RMS	Good LC	17 pts
Cotter SE et al	2012	retrospective	3b	<i>indication</i>	LC	Bladder/prostate RMS	Dose saving	7 pts
Timmermann B et al	2007	retrospective	3b	<i>indication</i>	LC	Pediatric sarcoma	Good LC	16 pts
Greiner R et al	1990	retrospective	3b	<i>indication</i>	LC	sarcomas	Spot scanning is feasible	35 pts
Nowakowski VA, et al.	1992	retrospective	2b	proton	LC	paraspinal	Feasible to deliver high dose	52 (14 sts)

Author	Year	Design	Evidence level	Intervention (comparator, if any)	Population	Outcome and results	Comments
Gannon et al	2019	Retrospective cohort, multi-institutional	2b	Surgery for extremity or truncal STS +/- RT	514 ptt., 2000 – 2016, U.S.A.	<p>stage I-III STS w pos margin: LR 11.1% (12/108) no RT vs 0% (0/7) preop RT; 4.2% (1/24) postop (P = 0.297).</p> <p>≤1 mm margin: LR 5.7% (2/35) no RT vs 0% preop (0/4), 0% (0/7) postop RT (P < .0001).</p> <p>>1 mm margin: LR 10.2% (28/272) no-RT vs 0% (0/18) preop RT, 3.7% (2/127) postop RT (P = .005). LRFS in all stage I-III patients + RT higher (P = .008)</p>	in microscopic pos margins, addition of RT may decrease LR to similar rates as negative margin resection.
Soydemir et al	2020	Retrospective cohort, single institution	3b	Surgery for extremity STS + RT	<p>64 ptt., 1996-2012, Turkey</p> <p>63 ptt had RT, but 8 of these 30 Gy or lower</p>	local recurrence was found in 19% of the low-grade patients, 45% of the moderate-grade patients, and 35% of the high-grade patients.	High recurrence rates, mash-up of palliative RT with curative RT.

						Mean OS for RT doses of ≤ 30 Gy 26.6 ± 15.5 months, of 30–60 Gy 75.5 ± 4.7 months, of 60 Gy 125.5 ± 16.2 months, of 66 Gy 97.8 ± 10.3 months, of ≥ 70 Gy 90.0 months ($P < 0.001$).	
Fahad et al	2024	Retrospective cohort, single institution	3b	Surgery for MFS, extremity or pelvic location, +/- RT	75 ptt., 2010–2022, U.S.A.	high rate of LR for the entire cohort (25/75, 33.34%) and for subgroups of with no radiation (18/50, 36%), postop RT (6/12, 50%), preop RT (1/13, 7.6%).	trend toward improved LC in preop RT, but no statistically significant reduction in RR (small cohort)
Raza et al	2023	Retrospective cohort, single institution	3b	Curative treatment with RT for extremity STS	122 ptt., 2017–19, Pakistan	106/122 had surgery; 11/122 preop RT; DFS 2y 62%; OS 5y 50%; 16 (13.1%) had LR; 24 (19.6%) distant metastases	Mean age 42 years
Gingrich et al	2020	Retrospective cohort, national database	2c	Adults undergoing surgery for SS +/- RT	1216 ptt.; 2004–2012, National Cancer Database, U.S.A.	60% + RT; RT associated with improved OS on multivariate analysis (HR, 0.676; 95% CI, 0.519–0.880; $p = 0.004$), chemotherapy (HR, 1.20;	Mean age 41 years

						95% CI, 0.899-1.60; $P = 0.217$) was not	
Naing et al.	2015	Retrospective cohort, national database	2c	Adults undergoing surgery for SS +/- RT	1189 ptt.; 1990–2009; SEER database, U.S.A.	57,5% + RT; univariate analysis: 5-y OS no RT $64.1 \pm 4.8\%$, with RT $72.5 \pm 3.8\%$ ($P = 0.003$). 5 y DSS no RT $67.7 \pm 4.8\%$, with RT $75.4 \pm 3.8\%$ ($P = 0.015$). Multivariate: RT (HR = 0.65, 95% CI 0.48–0.88) was associated with statistically superior OS ($P = 0.005$).	Mean age 41 years
Allignet et al.	2023	Retrospective cohort; single center	2b	Surgery after whoops excision of extremity or trunk STS +/- RT	145 ptt.; 2000–2015; France	108 ptt.s + RT; residual tumor in 48% of the cases; 10y LF in the aRT and no-RT groups: 14.7% and 37.7%, 10y-LRFS of 61.3% and 45.8%, respectively.	acute severe AEs increased if >50 Gy (RR 2.96, $P = .04$). >50Gy did not result in longer LRFS.
Fujiwara et al	2020	Retrospective cohort, single center	2b	Surgery for superficial STS +/- RT	304 ptt.; 1996–2015; 271 high grade; 210 + RT; only 4 ptt. with preop RT	LRFS significantly better for +RT in high grade tumors regardless of size, for close margins (<5mm); No difference in OS	

Chen et al	2024	Retrospective cohort, single center	3b	Surgery and postop RT for localized STS	52 ptt.; 17 R0; 35 R1 margin	No differences in LR R0 vs. R1 11% vs 35%, $p = 0.062$ or distant recurrence 40% vs 41%, $p = 0.93$	
Monga et al	2021	phase IB/II, open-label, non-randomized, prospective single-center trial	1b	ESTS or STS of the trunk; intratumoral injections of tVEC + neoadjuvant EBRT followed by definitive surgery	29 ptt.; 2015-2018; U.S.A.	2-y PFS 57%, 2-y OS 88%, 7/29 (24%) achieved 95% pathological necrosis	Median age 65 years; Preop RT (2Gy x 25, 5F/W) + intratumoral inj. of tVEC is feasible
Saxby et al	2022	Retrospective cohort, single center	2b	Surgery for primary high-grade STS	165 ptt., 2010 – 2019; U.S.A.	LR 15/78 (19%) no RT, 4/29 (14%) postop RT, 0/58 preop RT ($p=0.002$). Higher 2 y LR for MFS ($p=0.001$) and no-RT ($p=0.003$). MFS: 33(20%) of ptt., 12 (63%) of LR.	No RT after surgery with adequate margin >2mm in non-MFS might be ok
Zhang et al	2022	Retrospective cohort, single center	3b	Surgery + RT for STS of the superficial trunk	64 ptt., 2001-2018; U.S.A.; 50/65 IMRT	LC 5y 71%; for IMRT plans 78%	Median FU 57 months; Truncal STS is challenging even with IMRT
Preop RT							

Reijers et al	2023	Retrospective cohort, single center	2b	Preop RT + surgery of STS extremity and trunk wall	17 ptt.; 2010-2019; Netherlands. 2Gy x 25; 2Gy x 18 for MLS	LC 5y 91%; DMFS 5 y 61,8%; OS 5y 61,7%.; 18/107 RECIST PD; Radiologic response , viable cells or fibrosis not prognostic	Median FU 42 months; median age 61 y. No systemic treatment allowed.
Kaiser et al	2021	Retrospective cohort, single center	2b	Preop RT, localized STS	51 ptt.; 2006 – 2014, Schweiz, 12/51 MLS; 34/51 high-grade	MLS: Increased distance to vessels (1.1 [0–12.1] to 5.2 mm [0–32.70] (P=0.045), volume decrease from 517 (190–1124) to 257 cm ³ (89–685) (P=0.001).	
Allignet et al	2021	Retrospective cohort, single center	2b	Preop RT + surgery; STS extremity and trunk	121 ptt.; 2009-2020; France; UPS N=49; MFS N=19; MLS N=13, SS N=11	Median Relative Variation in Tumor Size: UPS: 0% (IQR -18- +18), MFS +8% (IQR 0- +24), MLS: -12% (IQR -20- -3) and SS: -11% (IQR -15 - -9) pCR: overall 27,7%; UPS: 36,7%; MFS 21,1%; MLS 38,5%; SS 9,1%; 2 y LRFS, DFS and OS: 84%, 68% and 86%	Median age 63y; median FU 35 months; only 5 LR, 3/5 in UPS.
Lansu et al	2021	prospective, multicenter, single-arm,	1b	Primary non-metastatic MLS, preop RT 2 Gy x 18, 5F/W	34 ptt.; 2010 – 2020;	median change of tumor volume, CC and axial diameter at preop MRI are -60% (IQR -74 to -41; p = 0.000), -19% (IQR -23 to -	Median age 45 y; increase in distance to

		phase 2 trial (DOREMY)			Netherlands; 33 pts had surgery	7; p = 0.000), and -20% (IQR -29 to -12; p = 0.000)	NVB by median 2mm; 32 ptt. R0
Ouyang et al	2024	Retrospective cohort, single center	2b	High-grade STS of limb/trunk; preop RT followed by surgery. 2 Gy x 25, 5F/W	116 ptt.; 2007-2021; U.K.	5-y DFS and OS: 52.9% and 70.3%; tumor size pre- and post RT, tumor volume, mitotic rate after RT, and mitotic rate change are sign. independent predictors for DFS, OS	Median age 59y; median FU for living patients 71,8 months; median tumor size 10 cm
Reirradiation							
Braschi et al	2021	Retrospective cohort, single center	2b	Surgery + RT for recurrent STS, and had surgery + RT before	23 ptt.; 1976 – 2014; U.S.A. Median RT dose at first surgery: 50,5 Gy; at recurrence: 55 Gy.	5y OS 39%; 5y LC 46%	median FU 46 months; 8 ptt. had amputation during FU
Side effects							
Folkert et al	2019	Retrospective cohort, single center	2b	RT and surgery for STS of thigh and groin	92 ptt.; 2002-2019; Canada; 86% postop RT.	5y risk of femoral fractures 6,7%; median time to fracture 23 months; multivariate analysis: higher	Median FU 73 months; all treated with IMRT plans;

						risk for age >60 and periosteal stripping >20 cm	constraints as in (81)
Dickie et al	2009	Retrospective cohort, single center	2b	Surgery and RT for lower extremity STS	691 ptt., 1989 – 2005; Canada.	31/691 ptt. developed radiation-induced fractures (RIF). 21 fracture ptt. (24 fractures) were matched to a random sample of 53 nonfracture ptt. Differences in mean, maximum dose, and V40 were statistically significant	risk of RIF reduced if V40 <64%, mean dose to bone <37 Gy or max dose along the bone <59 Gy
Casey et al	2020	Retrospective cohort, single center	2b	Surgery + IMRT for STS of the thigh or groin	145 ptt.; 2004-2016; 84 ptt. planned with dose constraints	5 y cumulative incidence of femoral fracture 1,8% w/constraints vs 7,4 % wo/constraints; not significant.	Median FU 6.1 y pre-constraints; 5,7y w constraints. Age >60 y significantly assoc w risk of fracture
Lansu et al	2019	Retrospective cohort study, multicenter	2b	preop RT and surgery for ESTS	191 ptt.; 2003 – 2017; Netherlands	LC 1, 3 and 5 y: 99%, 93% and 93%; Wound complications (WC) in n = 60 (31%); start median 25 days after surgery, median duration 76 days	Adiposity, smoking, LE, superficial ESTS sign. correlated w increased WC rate

Specific sites							
Munaretto et al	2020	Retrospective cohort, single center	3b	Surgery +/- RT for STS of hand or fingers	46 ptt.; 13 ptt. + RT; 1992 – 2013; U.S.A.	RT was not associated with a worse long-term functional outcome	Mean age 33 years; PRO data in 22 ptt.
Willis et al	2020	Retrospective cohort, single institution	2b	Surgery for primary or recurrent retroperitoneal sarcoma, IORT + EBRT postop or postop EBRT alone.	275 ptt., 2001 – 2016, Germany	5-year LR-free survival: IORT: 39%, non-IORT: 46%	
Hypofractionation							
Potkrajcic et al	2021	Retrospective cohort, two centres	2b	Frail patients unfit for long RT, with high-risk STS; 5Gy x 5, 5F/W	N = 18; 2018 – 2020; two German centres.	Median FU 5 months; LC at 6 months 92%	median age 83 y; feasibility incl. suggested constraints.
Kalbasi et al.	2020	Phase 2 single arm, single center	2b	STS of extremity or trunk, preop RT+ surgery; no CT; 6 Gy x 5, 5F/W	N = 50; 2014-2016; U.S.A.	2 ptt (5,7%) LR, 10 ptt. with DM. Major WC in 16/50 ptt. (32%); rate of grade ≥2 tox. (fibrosis, joint stiffness, lymphedema) 16%	2y FU in 38 ptt.
Delivery Technique							

Di Brina et al	2019	Retrospective cohort, single center	2b	Stage III STS of the extremities, all had surgery + RT	109 ptt.; 2004-2019; Italy; 38 ptt. 3DCRT, 71 ptt. VMAT	No difference in LC or OS	improved bones sparing; osteonecrosis only in 3DCRT; less skin tox.
Wang et al	2019	Retrospective cohort, single center	2b	STS of extremity or trunk; postop RT 50 Gy + boost 10-16 Gy	274 ptt.; 2005 – 2015; China; IMRT 187 ptt.; 2D-RT 87 ptt.	Overall 5-year LRFS, DMFS, DFS, and OS rates: 87.5%, 76.5%, 69.5%, and 87.0%; 5y LRFS 91,1% IMRT vs 80,8% 2D-RT p = 0.029; OS (90,2% vs 81%, p=0,029); significant difference in edema >= gr 2 9,2% IMRT vs 4,8% 2D-RT; joint stiffness >= gr 2 12,3% IMRT vs 3,9% 2D-RT; fracture >= G2 3,4% vs 1,1%	Median age 46 y; Median FU 58,1 months
Peeken et al	2019	Retrospective cohort, single center	2b	ESTS, preop RT on helical tomotherapy machine (IMRT-IGRT) + surgery;	38 ptt.; 2010 – 2014; Germany; 2 Gy x 25, 5F/W; reduced margins (1,5 cm axial; 2,5 cm longitudinal)	2y OS, local PFS and systemic PFS: 78.2, 85.2 and 54.5%; n=6 LR with proximal marginal misses; major WC 36,8%	Median age 58y; Median FU 38,5 months
Combined Pre- and Postop RT							

Konieczkowski et al	2021	Retrospective cohort, single center	2b	STS, +/- Low Dose (LD) preop RT + surgery + postop RT.	1980 – 2018; U.S.A.; 78 ptt. LD preop RT + surgery + postop RT; 394 ptt. surgery + postop RT	Tumors in postop RT group were smaller; in LD preopRT group 8y LC 76,7%; DFS 50%; OS 65,9%; No diff in OS, DFS, LC even after matching.	Median age in LD Preop RT group 51 y; median FU 8 y
Definitive RT							
Allignet et al.	2022	Retrospective cohort, single center	2b	Definitive RT for unresectable or R2 STS, oligomet disease allowed (<=5 lesions, 1 or 2 sites among soft tissue, lung, liver, and bones)	116 ptt.;2009 – 2020; France; median EQD2 60 Gy; 3D CRT 27 ptt.; IMRT 47 ptt.; SBRT 10 ptt.	3-year LF, PFS and OS: 43.2%, 16.6% and 34% 5- year LF 46.5%; ORR 22%; CT or dose >64 Gy not correlated to LF	Median FU 54 months; median age 71 y; 63 ptt received neoadj CT;

Appendix 6 - What's New - (Old change log)

Changes from version 1.1

Guideline section	Description of changes
Recommendations	<p>The wording and level of evidence of recommendation no. 22 has been changed; one out of 28 recommendations based on results from a new large phase III study (STRASS).</p> <p>The wording of recommendation no. 27 has been changed to refer to the latest EpSSG protocol (FAR-RMS) instead of EpSSG 2005.</p> <p>Text of "literature review and evidence description" on "site specific radiotherapy" section has been changed, recommendations no. 21 and 22.</p> <p>Text of "literature review and evidence description" on "pathology specific radiotherapy" section has been changed, recommendations no. 27 to refer to the latest EpSSG protocol (FAR-RMS).</p>
References	<p>Reference no. 67 has been removed from the referencelist and replaces with a new reference from the STRASS study.</p> <p>Reference no. 67 has been removed from the table and replaced with a new reference from the STRASS study.</p>
Appendix	<p>Appendix 3-1, "Rhabdomyosarcoma based on EpSSG 2005" have been replaces with "Rhabdomyosarcoma based on FAR-RMS protocol".</p>

8. About this clinical guideline

This clinical practice guideline is developed in collaboration between the Danish Multidisciplinary Cancer Groups (DMCG.dk) and the Danish Healthcare Quality Institute (SundK). The development is part of an intensified guideline effort launched in relation to the National Cancer Plan IV. The aim is to support high-quality cancer care across the Danish healthcare system. The guideline content is approved by the disease-specific Multidisciplinary Cancer Group, whereas the format is approved by the Center for Clinical Practice Guidelines | Cancer. Further information about clinical practice guidelines concerning cancer treatment in Denmark can be found here: www.dmcg.dk/kliniske-retningslinjer

The guideline targets clinically active healthcare professionals in the Danish healthcare system and contains systematically developed statements that can be used as decision support by professionals and patients when deciding on appropriate and correct healthcare services in specific clinical situations.

Clinical practice guidelines concerning Danish cancer care is characterized as professional advice. The guidelines are not legally binding and professional judgment in the specific clinical context will always determine what the appropriate and correct medical care is. Adherence to the guideline recommendations is no guarantee for a successful outcome. Sometimes care corresponding to a lower level of evidence will be preferred due to the individual patient's situation.

The guideline includes, in addition to the central recommendations (chapter 1 – quick guide), a description of the basis for the recommendations – including the underlying evidence (chapter 3), references (chapter 4), and applied methods (chapter 5).

Recommendations marked A are based on the strongest evidence, while recommendations marked D are based on the weakest evidence. For further information on strength of evidence see the "Oxford Centre for Evidence-Based Medicine Levels of Evidence and Grades of Recommendations", <https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>

This guideline also includes information on the target population (chapter 2) and the method of development (chapter 5) is also included in the guideline. See the table of contents for page references.

The guideline template has been prepared based on international quality requirements for the development of clinical guidelines as described by AGREE II, GRADE, and RIGHT.

For information on the Danish Health Authority's cancer packages – descriptions of the entire standard patient pathway specifying requirements for timelines and content – refer to the relevant disease area at: <https://www.sst.dk/en/english>

The Danish Health Authority (National Cancer Plan IV) and the Danish Healthcare Quality Institute (SundK) funded the development of this clinical practice guideline.